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The recent development of neural prosthetic technology has demonstrated a therapeutic 
potential for restoring lost sensory or motor functions via a brain-machine interface. Often the 
devices require direct contact between neural tissue and implanted electrodes to function 
properly by electrically stimulating or recording neurons on the scale of micro-volts. It is thus 
critical that the interface between the tissue and the electrode is seamless as well as stable for 
durations relevant to clinical applications. Unfortunately, the formation of an abiotic/biotic 
interface is often riddled with host tissue responses that interfere with device function. Neuronal 
loss due to insertion injury and chronic inflammation and exclusion of recordable cells by an 
encapsulated glial sheath have all been implicated as potential sources for chronic neural 
recording failure. Failure to establish a stable interface severely limits the function of implanted 
neural devices.  
In this work we rely upon interdisciplinary techniques in chemistry, biology, and physics 
to develop methods for the formation of a healthy brain-machine interface as well as new tools 
for the diagnostics of the tissue response. Through the creation of new biomaterials we have 
improved the neural interface, reduced local neurodegeneration around chronic implants, and 
demonstrated in vivo improvement of neural recording. In addition, novel conductive and 
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magnetic nanomaterials have been developed for electrochemically detecting reactive oxygen 
species associated with implant induced tissue damage as well as treatment strategies using on 
demand drug release. 
 By establishing a method for the formation of healthy and stable interfaces between 
neural tissue and electrode recording devices, the development of neural prosthetic devices can 
continue to progress towards clinical acceptance.  
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1.0   INTRODUCTION 
Interfacing with neural tissue is an incredibly complicated endeavor that holds the reward of 
restoring both lost motor and sensory function through neural prosthetic devices.1, 2 Given the 
unique electrical and chemical properties of the tissue, it is inherently an interdisciplinary field, 
interesting researchers in a wide array of backgrounds from electrical engineering and 
biomaterials, to computer science and mathematics. As scientists develop new technologies with 
neural interfacing applications, it is vital for a general understanding of a combination of both 
physical and natural sciences. Often this results in new materials being developed from a large 
team of researchers unconfined by a single discipline. In that spirit, the scope of this thesis is to 
outline the design of new technologies for the improvement of the tissue-electrode interface 
using a combination of molecular biology, synthetic chemistry, and physics. In large part, this 
work was of engineering motivation. While much of the described work will be valuable for our 
understanding of the mechanisms and underlying science of the tissue response to implanted 
devices, the true aim was to generate new technologies with translatable applications. For that 
reason, clinical relevance and potential acceptance is a focus of each chapter. The following 
chapters describe the design, preparation, and testing of new materials created with the goal of 
improving the lives of those impacted by the devastating effects of damage to one of the most 
important and delicate of tissues, the brain.  
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1.1 TISSUE-ELECTRODE INTERFACE 
In the U.S. alone there are approximately 50 million people affected by one of the nearly 600 
neurological disorders. Neurodegenerative diseases, which are classified by the progressive 
neuronal death within the nervous system, are not only emotionally exhausting to those affected 
and their families, but it is estimated that in the U.S. $100 billion are spent on health care costs 
for Alzheimer’s disease (AD) alone. Given that the risk for being diagnosed with AD doubles 
every 5 years after age 65, the economic burden this disease and others like it including 
Parkinson’s disease (PD), Huntington’s disease (HD), Amyotrophic Lateral Sclerosis (ALS), etc. 
continues to weigh heavily on the nation's aging populations.3, 4 
In recent decades a rapid increase in neurotechnology has enabled researchers across the 
globe to interact with the nervous system like never before. By implanting electrode probes into 
neural tissue, extracellular potential changes on the order of micro-volts can be recorded from 
individual neurons. Conversely, via the application of current into the system, neurons can be 
stimulated or inhibited resulting in network changes and even influencing behavior. This 
technology has been the foundation for the emergence of neural prosthetic devices which may 
someday restore lost motor or sensory function to the millions affected by spinal cord injuries, 
brain injuries, or neurodegenerative diseases.1, 2, 5, 6 Of course, the formation of an abiotic/biotic 
interface is often riddled with interfering biological responses and this technological problem is 
intensified when interfacing with neural tissue. Failure to establish a stable interface severely 
limits the function of implanted devices, especially those intended for clinical applications which 
in most cases would require proper function for the duration of the patient’s lifetime. 
Furthermore, the ability to record from individual neurons continues to increase our knowledge 
regarding the function of the brain.7 By establishing a method for the formation of stable 
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interfaces between neural tissue and electrode recording devices, the development of neural 
prosthetic devices can continue to progress in addition to the advancement of our ability to study 
the nervous system. 
1.1.1 Neurodegeneration 
Current attempts to record the chronic activity of individual neurons from implanted neural 
electrodes is variable between experiments and often limited in terms of consistently recording 
from the same neuron over time.8-10 Cell death resulting from implant insertion as well as chronic 
inflammation, and exclusion of recordable cells by an encapsulated glial sheath have all been 
implicated as potential sources for device failure. Given the limited range in which cells must be 
within to provide isolatable recording data, reversing the reduction of neuron numbers near the 
implant remains one of the key focuses of improving the interface.2, 11 Beyond the lack of 
recordable units, the degradation of the interface mediated by the glial response further hinders 
the possibility of recording from individual cells resulting in a significant increase of the 
electrical impedance of the recording sites.12 Improving the interface by preserving neurons near 
the implant and controlling the glial reaction will be critical in yielding functional chronic 
recording implants. 
Understanding the direct mechanism behind neuronal loss near chronically implanted 
electrodes is essential for the development of treatment paradigms that can improve the 
abiotic/biotic interface. Recent research has demonstrated that degenerating neuronal processes 
are observed near implant locations, a pathology similar to the neurodegeneration seen in 
hallmark neurodegenerative disorders such as Alzheimer’s disease.13 
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1.2 REACTIVE OXYGEN SPECIES 
The biochemical origin of the aforementioned neurological disorders is greatly varied. However, 
many of these diseases are unified by the progressive excitotoxicity and apoptosis of neurons that 
ensues. Given the role oxidative species play in these processes it stands that while the presence 
of reactive oxygen species (ROS) may not be the initiator of each of these diseases, ROS 
certainly mediate the pathology.4  In Alzheimer’s disease oxidative stress is elevated by the 
radical generation from an increase in trace metals such as Fe as well as free radicals produced 
directly from β-amyloid peptide (βAP) aggregated in the senile plaques.4, 14-16 Likewise, for 
several decades it has been well established that oxidative stress mediated lipid peroxidation 
plays a major role in nigral cell death associated with Parkinson’s disease.17, 18  Whether it is the 
ROS produced by macrophages which results in the demyelination observed in multiple sclerosis 
(MS), or the increased generation of free radicals from mitochondria following ischemia, it is 
clear oxidative species play a clear role in the mediation of numerous neurological disorders.19-21 
With recent demonstration of neurodegeneration near neural implants, it appears ROS may also 
influence the failure of chronically implanted neural electrodes.13  
1.2.1 Chemistry 
Oxidative stress is well known to be at the center of many diseases and disorders. In most 
references, oxidative stress is defined loosely as the outcome of high levels of reactive oxygen 
species that results in cellular damage. ROS are highly reactive oxygen containing chemical 
species that often contain an additional un-paired electron.22 While many ROS are in fact free 
radical species, this is not always so, as is the case with highly reactive single oxygen.23 
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Furthermore, a second related family of reactive species, reactive nitrogen species (RNS) are 
formed as a product of ROS in vivo.24, 25 The combination of ROS/RNS play a dynamic and 
intertwined role in cellular damage, cell signaling, and the inflammatory response. Collectively 
we will define reactions, whether chemical or biological, relating to these two families of species 
as reactive oxygen and nitrogen species (RONS). While RONS are often generalized as a single 
chemical output, an understanding of the individual biologically relevant species is vital to 
comprehension of the nuanced impact of oxidative stress. The entire list of RONS is lengthy; 
however, we place our focus on the most biologically relevant RONS produced in response to 
cellular damage. Superoxide (O2·-), nitric oxide (NO), peroxynitrite (ONOO-), hydrogen 
peroxide (H2O2), and the hydroxyl radical (OH·) are well understood to play pivotal roles in a 
variety of diseases including neurological disorders.26-28  
Understanding the relationship between ROS and RNS is an important step in designing 
new technologies targeting oxidative stress. Superoxide and nitric oxide are produced as both 
byproducts of reactions within a cell, for the purpose of cell signaling, and as inflammatory 
agents.29 Superoxide is produced as a byproduct of cellular respiration in the mitochondria; and  
typical levels are quenched by a class of proteins known as superoxide dismutase (SOD).30-33 
However, when cell damage occurs, the balance of superoxide production and elimination is 
tipped. What results is direct cellular damage by superoxide, but of more consequence is the 
diffusion-limited reaction with nitric oxide to produces the highly reactive nitrogen species, 
peroxynitrite (Figure 1-1). Within a cell the consequences of high levels of peoxynitrite are 
extremely toxic, resulting in the oxidation of protein and DNA as well as the peroxidation of the 
cell membrane.25, 34 
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Figure 1-1 Reactive Oxygen and Nitrogen Species Reaction 
 
1.2.2 Biological Sources 
Within the CNS, microglia act as the resident macrophage and upon activation transition from a 
ramified state to an amoeboid-like state. Once activated, microglia secrete pro-inflammatory 
cytokines, initiate the recruitment of additional macrophages/microglia, and produce various 
cytotoxic factors such as excitatory amino acids and reactive oxygen species (ROS).4 Given the 
proximity of microglia to implanted electrodes, nearby produced reactive oxygen species may 
directly result in an environment promoting neurodegeneration, especially considering that 
microglia up-regulate ROS when presented with insoluble promoters of activation.31, 32 Through 
the enzymatic production of superoxide and nitric oxide by NADPH oxidase and NO synthase, 
respectively, the oxidative stress produced by activated microglia results in neuron death. 
Furthermore, nearby dying cells effectively activate and recruit more microglia producing a 
positive feedback loop of neuronal death.33, 35, 36 Employing methods that would reduce reactive 
oxygen species may not only preserve the number of neurons nearby the electrode, but may also 
act to decrease the overall microglia response to the implant. 
The blood-brain barrier (BBB) is necessary to maintain homeostasis within the CNS and 
vital for neuronal health. Many diseases are implicated in blood-brain barrier dysfunction and it 
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is clear that disruption of the BBB has a negative effect on the function of chronic neural 
implants through recruitment of pro-inflammatory myeloid cells, increased presence of 
neurotoxic factors, as well as the activation of pathways that increase the levels of ROS.37, 38 To 
complicate matters further, reactive oxygen species have been shown to compromise endothelial 
tight junction proteins and subsequently increase the permeability of the BBB.39 It is not 
surprising then that activated microglia alone are sufficient to induce dysfunction of the BBB.40 
In a similar manner to microglial activation, disruption of BBB integrity by chronically 
implanted electrodes appears to form a positive feedback loop, corroborated by research showing 
long-term increased BBB permeability41, 42. While the circumstances regarding BBB dysfunction 
are certainly complex, the fact that the process is at least mediated by ROS provides the potential 
for treating oxidative stress that would improve both BBB integrity and further ameliorate the 
effects of activated microglia. 
Current analysis of oxidative stress and subsequent neurodegeneration around chronic 
neural electrodes is limited to histological end-point experiments.30-32 The short half-life and 
diffusion-limited reactions of reactive oxygen species make immunohistochemistry qualitative at 
best.43 The advancement of two-photon microscopy (TPM) allows researchers to now view 
individual cells within the brain in real-time providing information regarding neuronal activity as 
well as response to stimuli such as stroke.38, 44 With the use of dihydrorhodamine 123 (DHR 
123), an indicator of the ROS peroxynitrite, the extent of oxidative stress in ex vivo human skin 
after exposure to UV light shows promise for directly visualizing ROS in tissue.45 By combining 
two-photon microscopy with the unique specificity of DHR 123 for peroxynitrite, it may be 
possible to visualize oxidative stress near a neural electrode in vivo and in real-time. 
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1.2.3 Antioxidants.  
Given the widespread role ROS play in a variety of neurodegenerative diseases and 
disorders it makes oxidative stress a single therapeutic target for the treatment of a large variety 
of conditions. Typically, the level of oxidative stress is held in balance by the enzyme family 
superoxide dismutase (SOD), which can remove the superoxide through dismutation, a process 
that converts superoxide to molecular oxygen and hydrogen peroxide. However, using SOD to 
treat diseases that are influenced by oxidative stress, such as neurodegenerative diseases, has 
been for the most part unsuccessful due to low stability, poor bioavailability, and other negative 
factors including immunogenicity.31, 32  In recent years, the development of low molecular 
weight synthetic molecules that mimic the function of SOD has provided potential 
pharmaceutical agents for treating oxidative stress.30-33 One SOD mimic (SODm) in particular, 
manganese(III) meso-tetrakis-(N-ethylpyridinium-2-yl) porphyrin (MnIIITE-2-Pyp5+), has 
proven to be neuroprotective in in vitro models of Alzheimer’s disease as well as in in vivo 
models of stroke. Furthermore, MnIIITE-2-Pyp5+ is an equally capable peroxynitrite scavenger, a 
byproduct of the superoxide and nitric oxide released by microglia making it an ideal compound 
for reducing a variety of ROS produced in the context of neurological disorders.30-32 
1.3 L1 NEURAL ADHESION MOLECULE 
The development of biomimetic strategies has resulted in new technologies designed to improve 
the interface between neural tissue and implanted devices.46, 47 In efforts to reduce the host tissue 
response as well as promote neuron survival, coatings have been developed using components of 
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the extracellular matrix. The hope of technologies such as these, is to ‘mask’ inorganic devices 
like neural electrodes for the formation of a tight abiotoic/biotic interface. One such technology 
that has demonstrated great promise both in vitro and in vivo is the use of the neural cell 
adhesion molecule, L1CAM.  
1.3.1 Biological Origin 
Since its discovery in the mid-1980s, the L1 cell adhesion molecule has interested researchers in 
both the fields of neurodevelopment as well as biomaterials.48, 49 L1CAM is a transmembrane 
glycoprotein found along the axons of developing neurons and is responsible for interaction 
between cells.  The protein structure is composed of a larger extracellular region and a highly 
conserved cytoplasmic domain.48-52 The extracellular domain contains immunoglobulin and 
fibronectin-like regions that are responsible for the cell-cell interactions associated with L1CAM. 
The selective binding of L1CAM to integrins, extracellular matrix proteins, and homophilic 
interactions are critical for developing cells and important for neuron migration, axon growth, 
fasciculation, and even synaptic plasticity.  
1.3.2 Use for Neural Prosthetic Devices 
Given L1CAM’s unique ability to promote neuron attachment and cell survival, the protein was 
an ideal choice for the development of a biomimetic coating. Both recombinant forms of L1 and 
isolated protein from fresh brain tissue have been studied as a potential route for improving 
chronic neural electrode technologies.46, 47, 53 In addition to the improvement of neuron 
survivability, an additional benefit of L1 coatings is the reduction of inflammation around the 
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device. In previous work where the coating was applied to silicon-based neural electrodes, the 
tissue response to L1 coated arrays was mitigated.46, 47 Both an increase in relative neuron and 
neurites were observed in L1CAM coated arrays, as well as s reduction in inflammatory cells 
such as astrocytes and microglia.  
1.4 CONDUCTIVE AND MAGNETIC NANOCOMPOSITES 
The advancement of nanomaterials is essential for not only industrial coatings and applications 
but also the development of new highly functional medical devices. The concept of 
biocompatible films has transitioned from static coatings and materials into advanced materials 
that can be externally controlled and manipulated. For that reason an emphasis has been placed 
on materials containing conductive and magnetic properties.54, 55 These new controllable 
materials are redefining the manner in which we design new diagnostic and treatment 
technologies for biological tissue. 
1.4.1 Silica and Magnetic Nanoparticles 
Silica nanoparticles are widespread through the field of materials science. Given their ease of 
preparation and unique biocompatible properties, design and optimization of new silica 
nanoparticles is of great interest to biomaterials researchers.56-58 Furthermore, these materials can 
be effectively coupled with magnetic nanoparticle technology to result in a controllable and 
biocompatible nanocomposite with great potential. One of the key methods for preparing 
uniform silica nanoparticles is through the sol-gel process. The benefits of the sol-gel process is 
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that pure silica nanoparticles can be readily prepared and adjusted on the basis of size, 
distribution, and morphology by altering of reaction parameters and conditions. The general 
scheme is the preparation of a metal alkoxide solution which reacts to form a silicon polymer 
network through hydrolysis and condensation. This reaction can be catalyzed under either basic 
or acidic conditions.  
Incorporation of magnetic nanoparticles into silica nanocomposites allows for increased 
applications for these materials. Magnetic properties allows for improvements in magnetic 
imaging; however, magnetic separation and drivable hyperthermia properties are of increasing 
interest to researchers.19, 38, 43 Applications of static magnetic fields to magnetic nanoaprticles 
have been effective method for driving nanoparticle localization in tissue, as well as mass 
transport of nanoparitlce-bound cells. Both of which have great potential for drug delivery and 
regeneration applictions.38 In addition, the ability to cause local changes to the tissue through 
‘excitation’ of nanoparticles is increasing in interest. By applying high-frequency magnetic 
fields, micro-motion of nanoparticles can effectively increase the temperature of nearby tissue.43, 
59 This response has already provided researchers with a new tool to kill cancerous tissue. 
Furthermore, when tuned, this response can be contained within the nanoparticle, resulting in 
swelling of the nanomaterial. When combined with drug loaded nanoparticles, this has enabled 
researchers a new method for controlled drug release.  
1.4.2 Conductive Nanomaterials 
One of the benefits of conducting polymers in the field of bioelectronics is their use in the 
preparation of electrode films.60-63 The conductive nature of these materials is a result of the 
conjugated backbone that allows for electron transport through the delocalized π-bonds. In 
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addition oxidation of monomers in solution is easily performed that allows for polymerization at 
the surface of the electrode. Depending upon the monomer of choice, the resulting insoluble 
polymer contains either positive or negative charges. When electrodeposition is achieved in the 
presence of molecules or drugs of the opposite charge, these molecules can be effectively doped 
within the film. Furthermore, once on the surface of an electrode, these materials retain their 
conductivity and redox properties. Via the application of a reducing voltage potential, the 
reduction of the polymer backbone can be driven, releasing the doped drugs in the process. This 
property has resulted in the development of new controllable drug-release platforms.61 
1.5 DISSERTATION ORGANIZATION 
The work described within this dissertation is focused on the use of synthetic chemistry and 
materials science to create new coatings and materials for the improvement of the tissue-
electrode interface. In general the prepared materials are either directly targeting the mitigation 
of reactive oxygen species caused by the foreign body response, or are designed for the potential 
therapeutic delivery for antioxidant compounds. While the tissue response to inorganic implanted 
devices is certainly complex and composed of an incalculable number of biological signaling 
pathways, and inevitable consequence is the production of reactive oxygen and nitrogen species. 
Therefore, the goal of this dissertation is for the development of new techniques to reduce 
oxidative damage and thereby improve the tissue-electrode interface.  
In Chapter 2, the preparation of an antioxidant coating for neural probes is described. 
Using synthetic chemistry a novel superoxide dismutase mimic (SODm) is created and 
incorporated into a self-assembled monolayer (SAM) coating on neural electrodes. The material 
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demonstrated effective elimination of the superoxide, one of the main oxidative species produced 
by inflammatory glial cells. In addition to in vitro performance, the coating effectively improved 
the neuron density near implanted neural electrodes. The applications of this technology are far-
reaching and not limited to the improvement of neural technologies. The work described in 
Chapter 2 resulted in the development of patent pending technology. This technology is 
currently being licensed and commercialized by a material science company spun out of the 
University of Pittsburgh.   
Chapter 3 described the creation of a nanocomposite film designed for the purpose of 
improving electrochemical detection of superoxide. Through direct adsorption of the 
metallorporphyin complex, hemin, onto a conducting polymer nanocomposite comprised of 
poly(3,4-ethylenedioxythiophene) (PEDOT) and graphene oxide (GO), we have prepared a 
sensor capable of reliably detecting superoxide. Using the prepared hemin-PEDOT/GO sensor, 
we conducted a mechanistic study of the generation of superoxide by the enzyme complex, 
xanthine oxidase. In addition to providing a platform for our understanding of the mechanism 
behind the foreign body response, this sensor technology could be used to provide real-time 
assessment of neural implant health enabling clinicians to implement the appropriate treatment.  
Described in Chapter 4 is the efforts made towards dissemination and translation of a 
protein based biomimetic coating for neural implants. Built upon our laboratories L1CAM 
protein coating for neural implants, we have prepared a new methodology for coating FDA-
approved neural electrode arrays. In addition, described is the first isolation of the non-human 
primate L1CAM homologue. As a step towards pre-clinical development, the coating is applied 
to electronically functional arrays for non-human primate studies, where a general improvement 
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in neural recording quality is observed. The L1CAM coating optimized in this chapter has 
resulted in patent pending technology.  
The development of novel drug delivery systems using silica magnetic nanoparticles is 
described in Chapter 5. By combining the properties of silica nanomaterials and magnetic 
nanoparticles, a controlled-release system has been developed. Due to the magnetic nature of the 
created nanocarriers, controlled drug release can be stimulated using noninvasive application of 
high-frequency magnetic field. This technology is further developed to provide ‘proof-of-
concept’ evidence for drug delivery using clinical-grade MRI scanner equipment. Furthermore, 
for the precise application of incorporating a new drug-delivery system directly onto neural 
electrodes, a self-assembled monolayer magnetic nanoparticle coating is prepared. The 
nanoparticle coating improves neuron attachment and growth due to the magnetic nanoparticles 
of the coating and enables future development of magnetically controlled drug-release strategies 
for neural electrodes.  
Finally, Chapter 6 details the development of a conductive-magnetic nanocomposite 
designed for electrochemical drug release. We successfully prepared nanoparticles by 
encapsulating magnetic nanoparticles in a conductive polymer ‘shell’. Using this technique we 
incorporated the model drug, fluorescein and relying upon the magnetic separation of the 
prepared nanoparticles, electrodeposited the conductive-magnetic nanocomposite onto 
electrodes. These films were characterized by a rough, fibrous network, and greatly increased the 
drug release performance when compared to traditional doped polymer coatings. This technology 
could be used to improve neural electrodes by providing an effective drug-release platform for 
implanted devices.  
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In summary, the work described here represents a variety of techniques and methods for 
the improvement of the neural tissue-electrode interface. The reduction of oxidative species 
represents a promising strategy for increasing neuron survivability near implants.  Using both 
chemical and biological derived coatings has resulted in promising results that could translate to 
clinical applications. Finally with the preparation of nanomaterial based films and coatings, we 
have continued to improve the fields of both bioelectronics and drug-delivery. Each of these 
technologies could be impactful in the diagnostics and treatment of the inflammatory response 
around chronically implanted neural devices.  
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2.0  A SUPEROXIDE-SCAVENGING COATING FOR IMPROVING NEURAL IMPLANTS 
2.1 INTRODUCTION 
In recent decades neurotechnology has offered researchers new ways to interface with the 
nervous system. By implanting electrode probes into neural tissue, extracellular potential 
changes on the order of micro-volts can be recorded from individual neurons. Conversely, via the 
application of current into the system, neurons can be stimulated or inhibited resulting in 
network changes and even influencing behavior. This technology has been the foundation for the 
emergence of neural prosthetic devices which may someday restore lost motor or sensory 
function to the millions affected by spinal cord injuries, brain injuries, or neurodegenerative 
diseases.1, 2, 5, 6 However, implant performance is often riddled with interfering host tissue 
responses and this technological problem is intensified when interfacing with neural tissue. 
Failure to establish a stable interface severely limits the function of implanted devices, especially 
those intended for clinical applications which in most cases would require proper function for the 
duration of the patient’s lifetime. Furthermore, the ability to record from individual neurons 
continues to increase our knowledge regarding the function of the brain.7 By establishing a 
method for the formation of stable and seamless interfaces between neural tissue and electrode 
devices, the development of neural prosthetic devices can continue to progress in addition to the 
advancement of our ability to study the nervous system. 
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Current attempts to record the chronic activity of individual neurons from implanted 
neural electrodes is variable between experiments and often limited in terms of consistently 
recording from the same neuron over time.8-10 Cell death resulting from implant insertion as well 
as chronic inflammation, and exclusion of recordable cells by an encapsulated glial sheath have 
all been implicated as potential sources for device failure. Given the limited range in which cells 
must be within to provide isolatable recording data, reversing the reduction of neuron numbers 
near the implant remains one of the key focuses of improving the interface.2, 11 Beyond the lack 
of recordable units, the degradation of the interface mediated by the inflammatory glial response 
further hinders the possibility of recording by isolating the electrodes with a scar.12 Inhibiting 
neuronal dealth near the implant and controlling the inflammatory reaction will be critical in 
yielding long term high quality neural recording or stimulation[cite the caspase-1 paper]. 
Recent research has demonstrated that degenerating neuronal processes are observed near 
implant locations, a pathology similar to the neurodegeneration seen in hallmark 
neurodegenerative disorders such as Alzheimer’s disease.13 The biochemical origin of the 
aforementioned neurological disorders is greatly varied. However, many of these diseases are 
unified by the progressive excitotoxicity and apoptosis of neurons that ensues. Given the role 
oxidative species play in these processes it stands that while the presence of reactive oxygen 
species (ROS) may not be the initiator of each of these diseases, ROS certainly mediate the 
pathology.4  For several decades it has been well established that oxidative stress mediated lipid 
peroxidation plays a major role in nigral cell death associated with Parkinson’s disease.17, 18  
Whether it is the ROS produced by macrophages which results in the demyelination observed in 
multiple sclerosis (MS), or the increased generation of free radicals from mitochondria following 
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ischemia, it is clear oxidative species play a clear role in the mediation of numerous neurological 
disorders.19-21  
ROS are highly reactive oxygen containing chemical species that often present an 
additional un-paired electron.22 While many ROS are in fact free radical species, this is not 
always so, as is the case with highly reactive single oxygen.23 Furthermore, a second related 
family of reactive species, reactive nitrogen species (RNS) are formed as a product of ROS in 
vivo.24, 25 The combination of ROS/RNS play a dynamic and intertwined role in cellular damage, 
cell signaling, and the inflammatory response. Collectively we will define substances, whether 
chemical or biological, relating to these two families of species as reactive oxygen and nitrogen 
species (RONS). While RONS are often generalized as a single chemical output, an 
understanding of the individual biologically relevant species is vital to comprehension of the 
nuanced impact of oxidative stress. The entire list of RONS is lengthy; however, superoxide (O2·-
), nitric oxide (NO), peroxynitrite (ONOO-), hydrogen peroxide (H2O2), and the hydroxyl radical 
(OH·) are well understood to play pivotal roles in a variety of diseases including neurological 
disorders.26-28  
Understanding the relationship between ROS and RNS is an important step in designing 
new technologies targeting oxidative stress. Superoxide and nitric oxide are produced as both 
byproducts of reactions within a cell, for the purpose of cell signaling, and as inflammatory 
agents.29 Superoxide is produced as a byproduct of cellular respiration in the mitochondria; and  
typical levels are quenched by a class of proteins known as superoxide dismutase (SOD).30-33 
However, when cell damage occurs, the balance of superoxide production and elimination is 
tipped. What results is direct cellular damage by superoxide, but of more consequence is the 
diffusion-limited reaction with nitric oxide to produces the highly reactive RNS, peroxynitrite. 
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Within a cell the consequences of high levels of peoxynitrite are extremely toxic, resulting in the 
oxidation of protein and DNA as well as the peroxidation of the cell membrane.25, 34 
Within the CNS, microglia act as the resident macrophage and upon activation transition 
from a ramified state to an amoeboid-like state. Once activated, microglia secrete pro-
inflammatory cytokines, initiate the recruitment of additional macrophages/microglia, and 
produce various cytotoxic factors such as excitatory amino acids and reactive oxygen species 
(ROS).64, 65 Activated microglia/macrophages have been identified to be the primary cell type 
immediately contacting implanted electrodes.11 Given the proximity of these cells to the neural 
implants and their activation state, nearby produced reactive oxygen species may directly result 
in an environment promoting neurodegeneration, especially considering that microglia up-
regulate ROS production when presented with insoluble promoters of activation.66 Through the 
enzymatic production of superoxide and nitric oxide by NADPH oxidase and inducible NO 
synthase (iNOS), respectively, the oxidative stress produced by activated microglia results in 
neuron death. Furthermore, nearby dying cells effectively activate and recruit more microglia 
producing a positive feedback loop of neuronal death.64, 67, 68 Employing methods that would 
reduce reactive oxygen species may not only preserve the number of neurons nearby the 
electrode, but may also act to decrease the overall microglia pro-inflammatory response to the 
implant. 
The blood-brain barrier (BBB) is necessary to maintain homeostasis within the CNS and 
vital for neuronal health. Many diseases are implicated in blood-brain barrier dysfunction and it 
is clear that disruption of the BBB has a negative effect on the function of chronic neural 
implants through recruitment of pro-inflammatory myeloid cells, increased presence of 
neurotoxic factors, as well as the activation of pathways that increase the levels of ROS.37, 38 To 
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complicate matters further, reactive oxygen species have been shown to compromise endothelial 
tight junction proteins and subsequently increase the permeability of the BBB.39 It is not 
surprising then that activated microglia alone are sufficient to induce dysfunction of the BBB.40 
In a similar manner to microglial activation, disruption of BBB integrity by chronically 
implanted electrodes appears to form a positive feedback loop, corroborated by research showing 
long-term increased BBB permeability41, 42. While the circumstances regarding BBB dysfunction 
are certainly complex, the fact that the process is at least mediated by ROS provides the potential 
for treating oxidative stress that would improve both BBB integrity and further ameliorate the 
effects of activated microglia. 
Typically, the level of oxidative stress is held in balance by the enzyme family SOD, 
which can remove the superoxide through dismutation, a process that converts superoxide to 
molecular oxygen and hydrogen peroxide. However, using SOD directly to treat diseases that are 
influenced by oxidative stress, such as neurodegenerative diseases, has been for the most part 
unsuccessful due to low stability, poor bioavailability, and other negative factors including 
immunogenicity.31, 32  In recent years, the development of low molecular weight synthetic 
molecules that mimic the function of SOD has provided potential pharmaceutical agents for 
treating oxidative stress.30-33 One of the earliest superoxide dismutase mimic (SODm) complexes 
that has been tested in disorders relevant to oxidative stress and been incorporated into coatings 
for neural implants is manganese (III) tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP).69 
However, the negative charge of the complex combined with the fact that the redox potential was 
outside the window for catalytic dismutation of superoxide, resulted in the development of new 
complexes.70  
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One SOD mimic (SODm) in particular, manganese(III) meso-tetrakis-(N-
ethylpyridinium-2-yl) porphyrin (MnIIITE-2-Pyp5+), has proven to be neuroprotective in in vitro 
models of Alzheimer’s disease as well as in in vivo models of stroke. Furthermore, MnIIITE-2-
Pyp5+ is an equally capable peroxynitrite scavenger, a byproduct of the superoxide and nitric 
oxide released by microglia making it an ideal compound for reducing a variety of ROS 
produced in the context of neurological disorders.30-32 
Previous work to functionalize silicon-based neural electrodes by covalent attachment of 
biomolecules has shown great promise at improving the tissue-electrode interface.46, 47, 71 To 
reduce the oxidative stress and improve the neuronal survival near chronically implanted neural 
electrodes, we have designed a new coating based upon a synthetic derivative of MnIIITE-2-
Pyp5+. Described here are the synthesis and coating strategy, in vitro performance of coated 
substrates, and in vivo histological evidence demonstrating an increase in neuron survivability 
nearby SODm coated neural electrodes.  
2.2 MATERIALS AND METHODS 
2.2.1 Chemicals and Reagents 
The unsubstituted porphyrin, H2T-2-Pyp, as well as the metalloporphyrin, MnIIITE-2-Pyp5+ 
(manganese(III)-5,10,15,20-tetrakis(N-ethylpyridinium-2-yl)porphyrin)),  can be purchased from 
Frontier Scientific, Inc. (Logan, UT). Resveratrol as well as manganese (III) tetrakis (4-benzoic 
acid) porphyrin chloride (MnTBAP) were purchased from EMD Millipore Corp. The remaining 
chemical reagents, biological reagents, and solvents were purchased from Sigma Aldrich. 
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2.2.2 Synthesis of the Immobilizable Superoxide Dismutase Mimic (iSODm) 
The preparation of the alkylamine functionalized metalloporphyrin, MnIIITEA-2-Pyp5+ 
(manganese(III)-5,10,15,20-tetrakis(N-(2-aminoethyl)pyridinium-2-yl)porphyrin)) herein 
referred to as iSODm, occurs via a one-pot synthesis and direct metalation of the unsubstituted 
porphyrin H2T-2-Pyp (meso-Tetra (2-pyridyl) porphine). The unsubstituted porphyrin, H2T-2-
Pyp, was dissolved in DMF with excess 2-bromethylamine in a round bottom flask equipped 
with a refluxing condenser. The temperature was raised to 100 ºC and the reaction was kept 
under reflux for 24 – 48 hr. The extent of the reaction was measured via the progressive 
appearance of mono-, di- , tri-, and tetra- substituted porphyrin species monitored via thin-layer 
chromatography (TLC) using KNO3-saturated H2O-H2O-acetonitrile (1:1:8, v/v/v/) and the 
characteristic UV-Vis absorption peak at 414 nm. Following completion of the reaction to the 
tetra- substituted porphyrin, excess MnCl2 was added directly to the flask and the reaction was 
kept under reflux for an additional 24 – 48 hr. The progression of the reaction was monitored by 
observation of the Soret band after metallation shift to 450 nm. After the completion of the 
reaction, the solution was cooled to room temperature and the final metalloporphyrin product 
was precipitated by the addition of tetrahydrofuran (THF). The complex was filtered and washed 
with THF and diethylether. Purification was achieved via ion exchange and crystallization. The 
water-soluble product was dissolved in water and crystallized using a saturated ammonium 
hexafluorophosphate solution. The final water soluble product was prepared by dissolving the 
hexafluorophosphate salt complex in acetone and precipitation with tetrabutylammonium 
chloride. 
 23 
2.2.3 Electrochemical Characterization of the iSODm Complex 
Electrochemical measurements were performed in a glass cell containing a glassy carbon 
working electrode (3 mm in diameter), a Pt foil counter electrode, and an Ag/AgCl electrode (in 
1 M KCl solution) as a reference electrode using the Autolab Potentiostat/Galvanostat 
(Metrohm). Measurements were taken of 10 mM iSODm in 0.2 mM PBS, pH = 7.5 at a scan rate 
of 100 mV/s between -0.1 V to 0.5 V NHE. 
2.2.4 Immobilization of iSODm  
2.2.4.1 Cleaning and Pre-Treatment of Samples  
 
Glass coverslips or dummy A-style silicon based neural probes (NeuroNexus, Ann Arbor 
MI) were submerged in a 1:1 MeOH:HCl solution for 30 min. in a large crystallization dish with 
gentle agitation to remove organic residue. After rinsing with deionized water, concentrated 
H2SO4 was pipetted directly onto the samples. Following 30 min. of acid surface activation, the 
samples were rinsed with deionized water and dried under N2 flow overnight. 
2.2.4.2 Silanization 
 
Pre-treated glass samples or silicon probes were submerged in a 2.5% solution of the 
organosilane, (3-Mercaptopropyl) trimethoxysilane (in toluene) and shaken for 2 hr. inside a 
glove bag under N2. Afterwards, the samples were rinsed with copious amounts of toluene and 
sonicated in a water bath to remove excess unreacted silane. Sonicated samples were rinsed 
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again with toluene and allowed to dry under N2 flow. The heterobifunctional crosslinker sulfo-
gmbs (N-ɣ-maleimidobutyryl-oxysulfosuccinimide ester) was dissolved in minimal amounts of 
DMF and diluted to 0.5 mg/mL in absolute ethanol. The silanized surfaces were submerged in 
the sulfo-gmbs solution for 1 hr, then rinsed with absolute ethanol and dried. Finally, the 
functionalized iSODm complex was covalently attached to the activated surface by submerging 
the substrates in 1 mg/mL iSODm solution (PBS) for 1 hr. Successful coating was verified by 
confirmation of sulfur (silane) and manganese (iSODm)  using X-ray photoelectron spectroscopy 
(XPS) for elemental composition with a MCL – ESCALAB 250 XI Thermo Scientific XPS. 
2.2.5 Superoxide Scavenging Activity of iSODm 
To determine the catalytic superoxide scavenging nature of the synthesized iSODm complex in 
comparison to other antioxidants, the cytochrome C assay is used to monitor superoxide 
produced via the xanthine oxidase enzyme system. Superoxide (O2·-) was generated with 
xanthine oxidase (10 nM) and pterine (100 µM) in the presence of cytochrome c (50 µM) in 
PBS. To prevent interference from H2O2, 15 µg/mL catalase was added to the reaction. The 
reduction of cytochrome C by superoxide was monitored at 550 nm in the presence of different 




2.2.6 In vitro bioactivity testing of iSODm immobilized surfaces 
2.2.6.1 HAPI Cell Line 
 
Frozen Highly Aggressive Proliferating Immortalized (HAPI) microglia cells (provided 
by Dr. Xiaoming Hu, Department of Neurology, University of Pittsburgh) were thawed and 
passaged once before being plated at a density of 1 x 105 cells/cm2 in 24-well plates. Cells were 
plated directly onto glass coverslips. Cells to test the iSODm coating were plated directly onto 
glass coverslips that were coated with iSODm as described above. Cells to test the soluble 
antioxidants were plated directly onto glass coverslips in media containing either 10 µM 
MnIIITE-2-Pyp5+(SODm), MnTBAP, resveratrol, or diphenyleneiodonium (DPI). Before 
activation, cells were grown until ~ 80% confluence (24 hr) in serum containing media (10% 
fetal bovine serum, DMEM (Gibco 21041 DMEM/F12 +L-glutamine – HEPES – Phenol Red, 
Invitrogen, Carlsbad CA)). Cells were plated in triplicate per group and incubated at 37 ºC. 
2.2.6.2 Inflammatory Activation of HAPI Cells 
 
HAPI cells were incubated with stimulating agents to activate the immune response via 
either the Damage-Associated Molecular Pattern (DAMP) pathway or the Pathogen-Associated 
Molecular Pattern (PAMP) pathway. Following initial proliferation of cells, all cells were 
maintained in serum-free DMEM media and treatment conditions were replenished when 
changing media.  
For the PAMP pathway response, cells were stimulated with gram-negative bacteria-
derived lipopolysaccharide (LPS, from Escherichia coli) at a concentration of 10 ng/mL in the 
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presence of 2 ng/mL interfeuron gamma (IFNɣ). Cells were stimulated for 24 with LPS/IFNɣ 
stimulation prior to measurement of oxidative species or fixation. 
DAMP pathway activation was triggered with incubation in serum-free media containing 
5 µg/mL phobol 12-myristate 13-acetate (PMA). Cells were stimulated with PMA for 3 hr. prior 
to the measurement of oxidative species or fixation. 
2.2.6.3 Measurement of NO Output of Activated HAPI Cells 
 
Nitric oxide production of stimulated cells was measured using the commercially 
available Griess Reagent Kit (Invitrogen, Carlsbad CA). Samples of the cellular supernatant are 
taken and mixed with the Griess reagent. Following 30 min. incubation at room temperature, NO 
levels were measured by measuring the absorbance at 540 nm. For each group, NO levels were 
normalized by cell count and a percent change from unstimulated cells was compared using two-










2.2.6.4 Measurement of O2·- Output of Activated HAPI Cells 
 
Superoxide production by cells was monitored using the cytochrome C assay. In brief, 3 
hr. prior to the PMA stimulation endpoint, media containing 10 µM cytochrome C was added to 
each well. For antioxidant groups and inflammatory response treatments, the appropriate 
concentrations of the antioxidants/stimulating agents were included with the cytochrome C. 
Following 3 hr., the reduction of cytochrome C is measured at 550 nm. For each group, O2·- 
levels are normalized by cell count and a percent change from unstimulated cells was compared 
using two-way ANOVA, followed by Tukey’s post hoc analysis. A p-value of < 0.05 is 
considered significant. 
2.2.6.5 Intracellular Staining of Reactive Oxygen Species 
 
Intracellular staining of ROS was completed using the probe dihydrorhodamine (DHR) 
dye. Prior to the endpoint for all conditions, media containing 10 µM DHR was added to each 
well. For antioxidant groups and inflammatory response treatments, the appropriate 
concentrations of the antioxidants/stimulating agents were included with the cytochrome C. After 






2.2.6.6 In vitro Cell Staining, imaging and quantification 
 
Immunofluorescence was performed on HAPI cells fixed with 4% paraformaldehyde 
(PFA) for 10 minutes and blocked with 10% goat serum for 45 min. The following monoclonal 
primary antibodies were incubated at room temperature together at a dilution of 1:500 for 1.5 hr 
in 2.5% goat serum in PBS: mouse anti-ED1 (AdD Serotec, Raleight NC), rabbit anti-iNOS 
(inducible nitric oxide synthase, Millipore), and chicken anti-ARG-1 (arginase; Millipore). Cells 
previously stained with DHR (above) were incubated with rabbit anti-p47-phox (Millipore) for 
1.5 hr. After washing, the appropriate fluorescence-conjugated secondary antibodies were added 
in 2.5% goat serum for 1.5 hours. Cell nuclei were counterstained with Hoechst 33258 (2µg/mL; 
Sigma-Aldrich) at a dilution of 1:1000 in PBS. For a comparison of in vitro cell staining and 
DHR quantification, corrected total cell fluorescence (CTCF) was calculated. The integrated 
density of cell bodies was measured using ImageJ and substracted from the average normalized 
background (area of cell x mean fluorescence of background reading). The CTCF was compared 
using two-way ANOVA, followed by Tukey’s post hoc analysis. A p-value of < 0.05 is 
considered significant. 
 
2.2.7 Primary Neuron Cultures 
The ability of the iSODm coated samples to promote cell growth was examined by primary rat 
neuronal cell cultures. E18 Sprague-Dawley rat cortices were purchased from BrainBits, LLC. 
The rat cortices were triturated with a 1 mL pipette and removed from the Hibernate MediaTM 
via centrifugation at 800g for 1 minute. Cells were re-suspended in Neurobasal (Fisher)/B27 
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(Gibco)/0.5 mM glutamine/25 µM glutamate (Sigma-Aldrich) culture medium and plated 
directly onto either glass or iSODm coated glass coverslips in 24-well cell culture plates 
(Corning Costar) at a density of 2.5 x 105 cells/cm2. Cells were grown in culture for 5 days at 37 
°C in 5% CO2 and media was refreshed after day 3. Cells were fixed with 4% paraformaldehyde 
for 10 min. and stained with the monoclonal antibodies against neuronal class III β-tubulin 
(Covance) and the astrocyte-specific marker glial fibrillary acidic protein (GFAP) (Dako). 
Fluorescence images were taken using a fluorescence microscope and samples were evaluated 
for neuron attachment and neurite extension.   
2.2.8 1 Week Implantation of iSODm Coated Neural Probes 
2.2.8.1 Surgical Procedures 
 
Six adult male Sprague-Dawley rats (~ 350 g) were used throughout this study. Raw A-
style probes were implanted bilaterally with a total of 15 control (uncoated) and 15 iSODm 
coated arrays (N = 15).  A 1 week endpoint was investigated to determine the acute effect of the 
iSODm coating on neuron survivability. The animals were housed in University of Pittsburgh 
Department of Laboratory Animal Resources and given free access to food and water. All 
experiments and housing complied with the United States Department of Agriculture guidelines 
and were approved by the University of Pittsburgh’s Institutional Animal Care and Use 
Committee. Probes (Control or iSODm coated) were implanted bilaterally into the motor area (1 
mm anterior to Bregma, 2.5 mm Lateral), the somatosensory (2 mm posterior to Bregma, 2.5 mm 
lateral), and the visual area (4.5 mm posterior to Bregma, 2.5 mm lateral) in the cerebral cortex 
of the animal. General anesthesia was achieved with a mixture of 3% isoflurane in 1 L/min. O2 
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prior to implantation and was maintained at 1-2% isoflurane for the extent of the surgery. The 
state of anesthesia was closely monitored by observing the respiratory rate, heart rate, and 
absence of the pedal reflex. The animals were placed in a stereotaxic frame and their head was 
shaved, disinfected with isopropyl alcohol/betadine, and a sterile drape was placed over the 
surgical area. Ophthalmic ointment was applied to the animal, and the surface of the skull was 
exposed with a single incision along the midline. Three screw holes were drilled using a manual 
drill at each of the target areas (motor, somatosensory, visual) on both hemispheres. Two iSODm 
coated probes were implanted on the left hemisphere as well as one control probe (vice-versa for 
the opposite hemisphere).  In total each group had electrodes implanted into each area of the 
cortex. Prior to insertion of the probes, the dura layer was removed using a 30 gauge needle bent 
at 90°. The probes were inserted manually using a vacuum inserter device that held the delicate 
Raw probes. Following implantation, the craniotomies were filled with Kwik-Sil (World 
Precision Instruments, Sarasota FL) followed by FUSIO liquid dental cement. The skin was 
sutured around the dental cement head-cap and the animal was allowed to recover. 
2.2.8.2 Immunohistochemistry of brain tissue 
 
After the 1 week time point, animals were anesthetized with 50 mg/mL ketamine and 5 
mg/mL xylazine administered via the intraperitoneal (IP) cavity with a dosage of 0.1 mL/100 g 
body weight. The animals were transcardially perfused with 4% (w/v) paraformaldehyde in PBS. 
The brain was removed, taking care not to damage the implant site when removing the head-cap 
and post-fixed for 6 hr. The post-fixed brains were then equilibrated in 15% sucrose solution 
(4°C) overnight, followed by 30% for an additional 24 hr until the tissue sunk to the bottom of 
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the sucrose vial. The tissue was cut at 25 µm thick sections after cryoprotecting using optimal 
cutting temperature compound (OCT, Tissue-Tek, Torrance CA).  
Tissue sections at ~ 1000 µm deep were hydrated in PBS and blocked with 10% normal 
goat serum. Following 45 min in 0.5% Triton X-100 in PBS, the sections were incubated with 
the primary mouse monoclonal NeuN (1:500, Neuronal Nuclei, Millipore). The sections were 
rinsed and incubated for 1 hr in goat anti-mouse IGG Alexa 594 (Invitrogen, USA). All sections 
were counterstained using Hoechst nuclear die, cover-slipped and preserved with fluoromount-G. 
2.2.8.3 Fluorescent Imaging and Quantitative Brain Tissue Analysis 
 
Confocal fluorescent images were acquired using a FluoView 1000 (Olympus, Inc., 
Tokyo, Japan) at the Center for Biological Imaging. Images for each antibody were taken in a 
single session to reduce differences in microscope sessions during data analysis. For in vivo 
images, all sections were near 1000 µm depth to reduce variability in tissue. 
Neuron density was determined by counting neuron cell bodies stained with NeuN in 
concentric rings every 25 µm around the implant to 250 µm radially outwards. Total number of 
cells in each bin were counted using ImageJ. Neuron density per area was averaged for each 
implant group (Control vs. iSODm) and compared using two-way ANOVA, followed by 
Tukey’s post hoc analysis. A p-value of < 0.05 is considered significant. 
To compare the inflammatory response cellular markers for astrocytes (GFAP), microglia 
(OX42), and vascular leaking (IgG) were visualized. Average pixel intensity was calculated at a 
function of the distance from the probe, normalized to background tissue, and compared using 




2.3 RESULTS AND DISCUSSION 
2.3.1 Design and Characterization of iSODm 
The design of highly potent antioxidants is of great interest due to the role of oxidative species in 
cancer, neurologic disorders, traumatic brain injury, etc. In the realm of synthetic antioxidants, 
cationic metalloporphyrins such as MnIIITE-2-Pyp5+ have demonstrated some of the highest 
activity for superoxide scavenging.30 The key characteristic of MnIIITE-2-Pyp5+ that makes it 
such an effective antioxidant is that the complex’s redox potential (E1/2 = 230 mV vs NHE) lies 
roughly half-way between the oxidation (-160 mV) an reduction (890 mV) potentials of 
superoxide. To be an effective superoxide dismutase mimic (SODm) and to catalytically dismute 
superoxide, a metal complex must have a redox potential ~ 200 - 350 mV. The anionic 
metalloporphyrin MnTBAP was initially believed to be an effective SODm. However, combined 
with the complex’s low E1/2 which is nearly – 200 mV vs NHE, and the demonstration that 
impurities had bestowed earlier studies with SODm activity, research has determined MnTBAP 
to be an ineffective SODm.70 On the other hand MnIIITE-2-Pyp5+ has demonstrated 
extraordinarily high SODm activity as well as it’s antioxidant efficacy in several models of 




Therefore MnIIITE-2-Pyp5+ is considered an excellent candidate for incorporation into an 
antioxidant coating.31,32 To that end, we designed a metalloporphyrin that would retain the 
properties of MnIIITE-2-Pyp5+ which makes it an efficient SODm while adding amine functional 
groups that would provide coupling points for surface immobilization on to neural probe surfaces 











Figure 2-1 Chemical Structure for Novel Immobilizable SODm (iSODm).  
 
First, it was necessary to demonstrate the newly synthesized immobilizable SODm 
(iSODm) maintains the properties that would make it an effective SODm. To test this, cyclic 






























Figure 2-2 Synthesis Scheme for iSODm 
 
 First, it was necessary to demonstrate the newly synthesized immobilizable SODm 
(iSODm) maintains the properties that would make it an effective SODm. To test this, cyclic 
voltammetry (CV) was used to determine the redox potential of iSODm (Figure 2-3). The redox 
potential for iSODm was shown to be relatively unchanged from SODm at ~ 240 mV vs NHE, 
well within the catalytic window for superoxide dismutation.  
Then, to test whether the iSODm also demonstrated superoxide scavenger activity as 
SODm, the capacity of the complex to remove superoxide in the xanthine oxidase system was 
evaluated. Traditionally the xanthine-xanthine oxidase system has been the most widely used 
source of superoxide produced as a bi-product during the oxidation of xanthine to uric acid. 
However, uric acid in itself has radical scavenging capabilities and therefore we used the more 










Figure 2-3 CV Curve of iSODm at 100 mV/s in 1X PBS vs. NHE. 
The CV curve obtained of iSODm at 100 mV/s in 1X PBS vs. NHE. The E1/2 of the synthesized iSODm is 220 mV 
vs. NHE, within the window necessary for catalytic dismutation of superoxide. 
 
The superoxide-mediated reduction of cytochrome C in the presence of several 
antioxidants including iSODm, MnIIITE-2-Pyp5+, MnTBAP, and resveratrol was measured 
(Figure 2-4). Without any antioxidant treatment, cytochrome C reduction occurs at a constant 
rate indefinitely (PBS control), suggesting a constant supply of superoxide from the pterine-
xanthine oxidase system. Likewise, the addition of resveratrol does not decrease the rate of 
cytochrome C production.  
The antioxidant properties of resveratrol have been widely studied for many years. 
However, unlike catalytic SODm complexes, the antioxidant properties of resveratrol are 
believed to occur via suppression of NF-κB pathway following oxidative insult.72 Therefore its 
negative impact on superoxide production in this non biological assay is expected.  Also as 
expected by MnTBAP’s low E1/2, the anionic porphyrin is ineffective at preventing superoxide-
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mediated reduction of cytochrome C. Conversely, both MnIIITE-2-Pyp5+ and iSODm completely 
prevented cytochrome C reduction for the duration of the experiment, further verifying that 
iSODm remains a potent superoxide scavenger. 
 
 
Figure 2-4 Antioxidant Activity of iSODm Compared to Other Known Antioxidants. 
Antioxidant activity of iSODm compared to other known antioxidants. A constant supply of superoxide was 
generated using a Xanthine Oxidase/Pterine enzymatic system.  Superoxide concentration was measured via the 
stoichiometric reduction of ferricytochrome C (FCC) by superoxide. Only the cationic antioxidant, SODm and the 




2.3.2 In Vitro Antioxidant Effects of iSODm 
To evaluate the antioxidant performance of the iSODm coating, an in vitro model was 
used based upon an immortalized microglia cell line. Highly Aggressively Proliferating 
Immortalized cell line, or HAPI cells, are an immortal cell line of macrophage/microglia lineage 
that demonstrate an inflammatory response when stimulated with cytokines, lipopolysaccharide 
(LPS), etc.73 Given the nature of these cells, they are ideal for testing antioxidant performance 
under biologically relevant conditions of oxidative stress. Cells were either plated on glass (with 
or without antioxidant treatment in media) or glass coverslips coated with the iSODm. Following 
stimulation of the cells to activate the inflammatory response the oxidative output of the cells 
was evaluated in all conditions as well as the levels of several proteins important in oxidative 
species production.  
One of the key mechanisms of the DAMP pathway is the activation of protein kinase C 
and subsequent phosphorylation/activation of the NADPH oxidase.  The enzyme complex 
NADPH Oxidase functions to produce superoxide in monocyte derived cells including brain 
microglia as part of the inflammatory response. Phorbol myristate acetate (PMA) has been 
shown to activate protein kinase C and result in superoxide production of microglia cells via 
NADPH oxidase.42, 53 PMA stimulation was used as a model for superoxide production and the 
inflammatory response of microglia cells according to the DAMP pathway.  In addition to the 
iSODm coating and the other antioxidants, Diphenyleneiodonium was included as a control. 
Diphenyleneiodonium (DPI) has been shown to decrease superoxide-mediated cytochrome c 
reduction following NADPH oxidase activation of primary mouse monocytes/macrophages upon 
activation by 12-O-Tetradecanoyl-13-acetate (TPA).74 DPI functions by inhibiting the NADPH 
oxidase enzyme complex. Following stimulation of HAPI cells with PMA, we observed over a 
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350% increase in cytochrome C reduction in control cells (Figure 2-5).  Only cells plated on the 
iSODm coating or with MnIIITE-2-Pyp5+ in solution were at or below pre-stimulation levels. In 
fact, both treatments were significantly lower than DPI, the inhibitor of NADPH oxidase. As 
expected by the negligible antioxidant performance with the pterine-xanthine oxidase system, 
MnTBAP did not prevent superoxide-mediated cytochrome C reduction, nor did resveratrol.  
 
 
Figure 2-5 FCC Assay of PMA Stimulated HAPI Cells. 
FCC Oxidation is Prevented by iSODm coating following stimulation of PMA. FCC oxidation following PMA 
stimulation is completely abolished by both the iSODm coating and the SODm in solution (± SEM; n = 3; * p < 0.05 




Upon activation of protein kinase C, phosphorylation of the subunit p47 is translocated 
from the cytosol of the cell to the plasma membrane where it joins the other subunits of the 
NADPH oxidase complex.53 Following stimulation of HAPI cells with PMA, a significant 
increase in p47 staining is observed (Figure 2-6). This increase is significantly decreased when 
cells are plated onto the iSODm coating. Superoxide is known to increase protein kinase C 
activity and thus form a positive feedback loop for activity. Therefore, by decreasing superoxide 
levels, the overall inflammatory response of the cells can be lowered. 
  
Figure 2-6 Cellular levels of the NADPH Oxidase protein, p47phox in stimulated microglia cells. 
By using the corrected total cell fluorescence, a significant increase in p47 staining is observed in control microglia 
cells following treatment with either PMA or LPS. The CTCF from p47 staining is significantly lower in cells plated 
on the iSODm coating following PMA stimulation (± SEM; n = 20; * p < 0.05 compared to glass control; † p < 0.05 
compared to glass treatment). 
 
Lipopolysaccharide (LPS) is well established as an effective stimulating agent to induce 
the inflammatory response of microglia via the Pathogen-Associated Molecular Pattern (PAMP) 
pathway. Following activation by LPS/IFNγ, the activity of inducible nitric oxide synthase is 
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increased resulting in production of nitric oxide. To measure NO production in cells stimulated 
with LPS/ IFNγ, the commercially available Griess Reagent Assay was used. Interestingly, both 
the cationic porphyrin (iSODm) treatments and the anionic porphyrin (MnIIITE-2-Pyp5+ ) 
resulted in significantly increased NO output as measured by the Griess Assay (Figure 2-7).  
 
 
Figure 2-7 Griess Assay of LPS/IFN Stimulated HAPI Cells. 
Production of NO is only reduced with pre-treatment of the antioxidant resveratrol. Both cationic and anionic 
catalytic antioxidants result in a dramatic increase in measured NO (± SEM; n = 3; * p < 0.05 compared to glass 
control; † p < 0.05 compared to group control). 
 
Conversely resveratrol decreased NO output by more than 400% when compared to 
control. NO output altogether was nearly abolished with the NADPH oxidase inhibitor DPI. 
Although DPI has been shown to inhibit NADPH, it has been demonstrated in the literature that 
iNOS activity requires at least a threshold level of NADPH oxidase activity.29 In addition when 
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looking at immunostaining for iNOS, a significant increase in iNOS signal in LPS/IFNγ cells 
plated on iSODm coated samples is observed (Figure 2-8). The relative increase in NO output as 
measured by the Griess Assay as well as an increase in iNOS staining may be a result of the 
decrease of NO breakdown (as opposed to increase in production), which is dependent upon 
superoxide concentration (and subsequent formation of peroxynitrite)25. 
 
Figure 2-8 Up-Regulation of iNOS Following LPS/IFN Stimulation. 
Staining of iNOS is pronounced following LPS stimulation of microglia cells. The corrected total cell fluorescence 
is significantly higher in microglia following LPS stimulation, and significantly increased further in cells plated on 
the iSODm coating (± SEM; n = 20; * p < 0.05 compared to glass control; † p < 0.05 compared to glass treatment). 
 
 As shown in previous literature, the presence of superoxide scavenger such as SOD, NO 
breakdown is drastically decreased resulting in overall higher levels.42 In addition, NO, like 
superoxide, operates in a positive feedback method resulting in an increase in iNOS activity. 
These findings are consistent with what has been found on iSODm confirming the expected 
efficacy of the SODm. In addition, higher levels of arginase is observed in cells plated onto the 
iSODm coating (Figure 2-9). Arginase activity is typically related to the ‘wound-healing’ 
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response of macrophage type cells and mostly inversely proportional to iNOS activity. However, 
in this case high levels of both proteins for cells plated on the iSODm coating is observed. While 
iNOS is traditionally viewed as part of the inflammatory response, it has been shown that 
without superoxide production (and subsequent peroxynitrite production) NO levels can be 
cytoprotective and important for angiogenesis.64 
 
 
Figure 2-9 Arginase Activity in Stimulated HAPI Cells. 
Arginase staining decreases upon stimulation of LPS in control microglia cells as measured by the corrected total 
cell flourescence. However, arginase signaling is significantly increased across all iSODm coating groups (± SEM; n 
= 20; * p < 0.05 compared to glass control; † p < 0.05 compared to glass treatment). 
 
Using the superoxide probe, dihydrorhodamine (DHR), the intracellular levels of 
superoxide were evaluated (Figure 2-10). The non-fluorescent probe, DHR readily crosses the 
cell membrane; however, once it has reacted with superoxide it becomes the charged and 
fluorescent compound, rhodamine 123. When rhodamine 123 (Rho123) is produced via the 
reaction between DHR and superoxide in the cell, Rho123 can no longer leave the cell, enabling 
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detection of intracellular superoxide levels. Microglia significantly increase in fluorescence 
following both PMA and LPS stimulation, suggesting an important role in intracellular 
superoxide levels in the inflammatory response. However, when cells are plated on the iSODm 
coating, these intracellular levels of superoxide are abolished. 
  
Figure 2-10 Intracellular ROS 
Upon stimulation with either PMA or LPS, intracellular superoxide increases in microglia according to a significant 
increase in corrected total cell fluorescence. In all cases, intracellular superoxide is decreased in cells grown on the 








To determine effect of the iSODm coating on neuron growth, primary cortical cultures 
were grown on the iSOD coated coverslips for up to 5 days. Neuron density and neurite 
outgrowth were both dramatically increased on iSODm (Figure 10Figure 2-11). Besides the 
antioxidant properties of the coating, neuron growth has also been demonstrated to be improved 
with positively charged surfaces such as poly-lysine which shares structural similarities with the 
iSODm complex. In addition, the adhesion of microglia is decreased when plated on the iSODm 
surface. These two added benefits may provide optimal tissue interaction of implanted materials 











Figure 2-11 Neuron Growth on iSODm Coated Substrates. 
Primary neuron cultures grown on samples with or without the iSODm coating. After 5 days, few primary microglia 
(β-III tubulin) or astrocytes (GFAP) are observed on glass samples. Both Neurons and Astrocytes readily grow on 
the cationic iSODm surface and neurite outgrowth is observed. 
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Neural electrodes modified with iSODm were implanted into rat cortex to investigate the 
effects an antioxidant coating had on neuron survival near the implant.  Neuron numbers were 
compared between unmodified and iSODm-modified electrodes by counting cell bodies 
indicated by NeuN staining, a neuron cell body specific histological stain. Neuron cell bodies 
were counted within a 250 µm radius from the implant location and binned by 50 µm (Figure 
2-12). Neuron death and neurodegeneration has been previously observed as early as 24 hr after 
neural electrode implant.13 When comparing unmodified electrodes with iSODm-modified 
electrodes, improvements in neuron density from the first bin (0 µm – 50 µm) to the last bin 
counted (175 µm – 250 µm) were observed. Based on the in vitro results, improvements in the 
neuron density near the neural electrode could be a result of the dual antioxidant and neuron 
promotion of the iSODm coating. However, improvements to the neuron density beyond the 
closest region to the implant are more likely to be a result of solely the antioxidant effects of the 
coating. As has been described previously, neurodegeneration around neural implants spreads 
out from the ‘kill zone’ and continues to decrease cell density as far out as 300 µm.13 The 
improvement in neuron survival may be due to the decrease in the oxidative environment in the 
nearby tissue. No differences were observed in microglia (OX42), astrocyte (GFAP), or bleeding 
(IgG) between unmodified and iSODm coated probes (Figure 2-13, Figure 2-14, Figure 2-15, 
respectively). However, considering the increase in neuron density around the iSODm coating, 
these cell types may be in different activation states.  
Traditionally, as tissue dies near the implant site, oxidative species would be produced 
both by necrotic cells and inflammatory glial cells.64 These oxidative species have been 
implicated in neurodegeneration and would explain the long-distance decrease in neuron density 
previously observed. However improvements of the neuron density as far out as 250 µm would 
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indicate a disruption of this oxidative pathway. Therefore, not only does the iSODm surface 





Figure 2-12 Neuron density is increased around iSODm coated Electrodes after 1 week.  
Neuron density was calculated by counting neuron cell bodies (NeuN) at a cortical depth of ~ 1000 µm. Neuron 
count is significantly higher around probes coated with iSODm in the most crucial 50 µm as well as beyond 100 µm 









Figure 2-13 OX42 Analysis around Neural Implant after 1 Week. 
 Normalized intensity analysis of OX42 staining was compared between unmodified and iSODm coated probes. The 
intensity difference was compared at 50 µm. There was no significant difference between unmodified and iSODm 
coated neural probes after 1 week (± SEM; n = 15).  
 
 
Figure 2-14 GFAP Analysis around Neural Implant after 1 Week.  
Normalized intensity analysis of GFAP staining was compared between unmodified and iSODm coated probes. The 
intensity difference was compared at 50 µm. There was no significant difference between unmodified and iSODm 
coated neural probes after 1 week (± SEM; n = 15).  
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Figure 2-15 IgG Analysis around Neural Implant after 1 Week. 
 Normalized intensity analysis of IgG staining was compared between unmodified and iSODm coated probes. The 
intensity difference was compared at 50 µm. There was no significant difference between unmodified and iSODm 
coated neural probes after 1 week (± SEM; n = 15).  
2.4 CONCLUSIONS 
A novel coating based on a newly synthesized antioxidant superoxide dismutase mimic was 
successfully created. By preparing a functionalized SODm derivative, a monolayer coating was 
created that demonstrated similar antioxidant effectiveness as MnIIITE-2-Pyp5+. Based upon in 
vitro results, the iSODm coating effectively reduced superoxide production resulting in a 
decreased oxidative environment which ultimately affected HAPI cell signaling pathways by 
altering protein levels of iNOS, NADPH oxidase, and arginase. Following 1 week of the implant, 
a significant increase in neuron density around the implant site surrounding iSODm coated 
arrays was observed. Furthermore, the effective radius of the iSODm coating was surprisingly 
beyond 250 µm from the implant location suggesting an interruption of the typical 
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neurodegeneration propagation. The development of this iSODm coating could ultimately result 
in the improvement of implantable neural devices and aid in the clinical progression of these 
technologies.  
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3.0  ELECTROCHEMICAL DETECTION OF SUPEROXIDE USING HEMIN-ADSORBED 
GRAPHENE OXIDE NANOCOMPOSITE 
3.1 INTRODUCTION 
Clinical application of neural prosthetic devices is prevented due to the poor performance of 
these devices at chronic time points.1, 2, 9, 11 While neuron proximity is the most important 
necessity for effective recording of neural signals, implanted devices are susceptible to an 
inflammatory response that creates a harsh environment. Often times an increased inflammatory 
response is coupled with progressive neuron cell death, or neurodegeneration.13 Understanding 
the mechanism behind neurodegeneration near neural implants is of the greatest importance in 
designing new strategies for improving the tissue-electrode interface. To aid such fundamental 
understanding,  real-time evaluation of the tissue state would be desired. 
Neurodegeneration is a complicated process by which neurons die, often as a result of 
either acute trauma or chronic disorders. While the underlying mechanism for the onset of 
neurodegeneration may be different depending upon the condition, it is widely accepted that 
reactive species such as free radicals, reactive oxygen species (ROS), or reactive nitrogen species 
(RNS) play a role in mediating the cellular death.3, 4, 41, 65, 75 One of the most studied reactive 
oxygen species, superoxide (O2·-), can result in cellular damage through direct lipid 
peroxidation, DNA degradation, or the creation of even more highly reactive chemical species.76-
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78 For this reason understanding the relative concentrations of superoxide is critical to diagnosing 
oxidative damage in vivo and in real-time. 
Directly detecting levels of ROS/RONS in vivo is a complicated task considering the 
species high rate of reactivity. Furthermore, current histological methods provide only indirect 
evidence of oxidative damage, and often are incapable of demonstrating the dynamic role that 
oxidative species play in trauma.13, 66 Given the need for real-time assessment of oxidative 
species, and the electrochemical origin of free-radical species, electrochemical detection methods 
have been a focus of ROS/RNS research. Often sensors are designed with inorganic sensing 




Figure 3-1 Superoxide Oxidation-Reduction Scheme 
 
Efforts into designing electrochemical sensors for superoxide production have been 
limited by poor incorporation of sensing elements into prepared devices.79 Using our laboratories 
previously established methods for improving sensor electrochemical properties, we have 
designed a hemin-based sensor through direct adsorption onto poly(3,4-ethylenedioxythiophene) 
(PEDOT) and graphene oxide (GO) nanofilms. We have demonstrated that using our hemin-
PEDOT/GO electrode we are not only capable of detecting biologically relevant concentrations 
of superoxide, but also able to effectively detect superoxide during a mechanistic study. 
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3.2 MATERIALS AND METHODS 
3.2.1 Chemicals and Materials 
For preparation of electrode nanocomposites, hemin, 3,4-Ethylenedioxythiophene (EDOT),  and 
phosphate buffered saline (PBS, pH 7.4, 10 mM sodium phosphate and 0.9% NaCl) were 
purchased from Sigma-Aldrich. Graphene Oxide was purchased from Cheap Tubes Inc. 
(Brattleboro, USA). The reagents for preparation of the superoxide generation system, xanthine 
oxidase, pterine, catalase, and cytochrome C were also purchased from Sigma-Aldrich.  
3.2.2 Electrochemical Apparatus 
Electrochemical pretreatment and deposition of nanocomposite films were performed with a 
Gamry Potentiostat, FAS2/Femtostat (Gamry Instruments).  For electrochemical detection 
experiments using cyclic voltammetry, an Autolab Potentiostat/Galvanostat PGSTAT128N was 
used. For both electrode preparation and electrochemical detection experiments, a traditional 
three-electrode setup was used. Glassy carbon electrodes served as a working electrode, a 
silver/silver chloride reference electrode (CH instruments) and a platinum foil counter electrode.  
3.2.3 Preparation of Hemin-PEDOT/GO Electrode 
Electrochemical deposition of a PEDOT/GO nanocomposite was performed on glassy carbon 
electrodes (GCE, 3 mm diameter, CH instruments). Prior to electrodeposition, electrodes were 
pre-treated. GCEs were first polished with 1.0 and 0.05 µm alumina slurries and then directly 
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ultrasonicated in ethanol followed by Millipore H2O. Finally, GCEs were electrochemically 
pretreated in 1 X PBS using both chronoamperometry (1.8 V for 200s) as well as cyclic 
voltammetry (5 cycles, 0.3 V to 1.3 V at 100 mV/s s.r.). Following pre-treatment, all GCEs were 
stored in 1X PBS to maintain the hydrophilicity. Conducting polymer films were prepared as 
described previously by our laboratory.62 PEDOT/GO films were electrochemically deposited 
using a deposition solution containing EDOT (0.2 M) and GO (10 mg/mL). Charge limited 
deposition proceeded by applying a constant potential of 1.0 V until the charge density reached 
100 mC/cm2 on the macroelectrode. 
Following electrochemical deposition, Hemin-PEDOT/GO electrodes were prepared by 
adsorbing hemin directly onto PEDOT/GO coated GCEs. A stock solution of hemin was first 
prepared by dissolving hemin in minimal 1 M NaOH and diluting with 1 X PBS to a final 
concentration of 10 mg/mL. The PEDOT/GO electrodes were submerged in the hemin solution 
for 24 hr and rinsed repeatedly with Millipore water prior to beginning sensor experiments.   
3.2.4 Electrochemical Characterization of Hemin-PEDOT/GO Electrode 
For characterization of Hemin-PEDOT/GO films as well as sensing experiments, cyclic 
voltammetry (CV) was used. A multiplex setup was used to decrease variance from solution 
preparation and to measure the same superoxide solutions with different probes. CV was 
measured from -0.8 V to 0.8 V at a scan rate of 100 mV/s. Initial CV measurements before and 
after electrode preparation were collected in 1 X PBS.  
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3.2.5 Generation of Superoxide 
A similar enzymatic generation system for superoxide production was used as described above 
(2.2.5). However, the setup was modified to account for the iterative nature of the experimental 
design. For each trial, 3 different electrodes were placed into an electrochemical cell containing 
15 mL of PBS. In between each addition to the cell, electrochemical measurements were 
collected. The first addition was catalase and xanthine oxidase, followed by pterine. For 
mechanistic studies, additional quantities of xanthine oxidase were added. 
3.2.6 Analysis of Superoxide Detection Data 
For analysis of the electrochemical data collected from the sensor experiments, a custom 
MATLAB script was created. The script allowed for measurement of both the peak cathodic and 
anodic current at the selected potentials. The oxidation and reduction peaks used to measure the 




3.3 RESULTS AND DISCUSSION 
3.3.1 Design and Characterization of Hemin Electrode 
Metalloporphyrins are of great importance to the biosensor field given their effectiveness as 
sensing elements for a variety of electrochemical reactions. In particular the sensing of reactive 
oxygen (ROS) and nitrogen species (RNS) is highly dependent upon metalloporphyrin-based 












Figure 3-2 Structure of Hemin Sensing Element 
 
Superoxide is one of the most interesting of the ROS/RNS given the radicals importance 
on cellular respiration, cell signaling, neurodegeneration and a wide variety of diseases.54 Using 
the protoporphyrin IX complex, hemin, scientists have worked on creating sensors to measure 
superoxide protection in real time (Figure 3-2).56, 83, 84 However, detection currents are often low 
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and un-reliable. To that end, we have designed a hemin-based sensor for the detection of 
biologically relevant superoxide concentrations. 
To create a highly sensitive sensor for superoxide we relied upon direct adsorption of 
hemin onto PEDOT/Graphene Oxide electrodes. By combining the properties of the conducting 
polymer PEDOT with the unique chemical properties of graphene oxide, our laboratory has 
previously demonstrated an improvement biosensing application based on the nanocomposite’s 
effects on impedance, charge-storage-capacity (CSC), etc.62, 63 Furthermore, the structure of 
graphene oxide results in excellent adsorption of hemin and similar metalloporphryin complexes 
(Figure 3-3).84 Given the highly conjugated structure for both the porphyrin backbone of hemin 
and graphene oxide itself, it is no surprise that tight adsorption of hemin onto graphene oxide and 
related structures has been demonstrated.85 
 
 
Figure 3-3 Structure of Graphene Oxide 
 
Like other metalloporphyrin complexes, the oxidation and reduction of the iron 
conjugated at the center of the porphyrin results in clearly visible oxidation/reduction peaks 
using cylic voltammetry experiments. Prior to preparation of a hemin-PEDOT/GO electrode, we 
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verified the oxidation/reduction peaks in a 1 mM solution of hemin in PBS. Using glassy carbon 
electrodes we observe oxidation/reduction peaks centered at ~ - 400 mV (Figure 3-4).  
 
 
Figure 3-4 CV Curve for Hemin 
The CV curve of 10 mM hemin in a PBS solution using a glassy carbon electrode (scan rate = 100 mV/s). 
 
Once we had confirmed the hemin peaks in solution, we focused on preparation of a 
hemin-PEDOT/GO electrode. Deposition of PEDOT/GO film onto working macro-electrodes 
resulted in broadening of the CV curve; however, no peaks were present at the expected location 
of the hemin peaks (Figure 3-5). The increased area within the PEDOT/GO film is consistent 
with our previous work and reflective of an increase in the charge storage capacity of the film.62 
For preparation of the final sensor, hemin was directly adsorbed onto the surface of the 
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PEDOT/GO film. As expected, hemin peaks were evident with a redox potential at ~ -400 mV. 
However, interestingly, the charge storage capacity of the film decreased. Considering no 
delamination or visible damage of the films was observed following the adsorption, the change 
to the electrochemical properties of the film must be a result of the interaction between hemin 
and the graphene oxide in the film. It is well established that hemin complexes interact with 
graphene oxide and graphene-like materials through π-π interaction of the aromatic porphyrin 
rings and the aromatic graphene backbone. Among other properties, this results in an increase in 
the electron transfer rate and charge dissipation rate of the film, both of which may decrease the 






Figure 3-5 Adsorption of Hemin onto GO/PEDOT GCE 
A comparison of the CV curves for a glassy carbon electrode (grey), a glassy carbon electrode following 
electrodeposition of GO/PEDOT (black), and a GO/PEDOT electrode following hemin adsorption (red).  
 
3.3.2 Sensitivity of Hemin Electrode 
The capacity for electrochemical detection of superoxide was compared between two 
electrode types. Hemin was directly adsorbed onto glassy carbon electrodes with or without a 
PEDOT/GO electrodeposited film.  For the generation of superoxide, the xanthine oxidase 
system was used. The xanthine oxidase system is an effective method for generating a consistent 
rate of superoxide for a long duration.25 Traditionally, xanthine oxidase is used in conjunction 
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with xanthine as a substrate. The oxidation of xanthine to uric acid results in the production of 
superoxide into the system. However, considering the antioxidant nature of uric acid itself, a 
slightly altered system was used. Pterine was used in place of xanthine to produce superoxide to 




Figure 3-6 Hemin Electrochemical Sensing Scheme 
 
The detection of superoxide by the hemin-PEDOT/GO electrode is dependent upon the 
electrochemical reaction occuring at the metal-centered metalloporphyrin (Figure 3-6). The 
oxidation and reduction peaks observed on the CV curves are a result of the oxidation and 
reduction of the iron ion at th center of the porphyrin complex. As the potential scans negatively, 
reduction of the hemin3+ complex occurs resulting in cathodic current. Conversely, as the 
potential scans positively, oxidation of hemin2+ results in the anodic peak. The relative 
magntidue of the cathodic and anodic peaks depend upon the concentrations of hemin3+ and 
hemin2+, respectively. In the presence of superoxide, the concentrations of redox ‘eligible’ hemin 
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is artificially increased. Again, let us consider the case when the potential is scanning negatively. 
Following reduction of hemin3+, [hemin2+] is high. When superoxide is available, hemin2+ is 
oxidized back to hemin3+. The superoxide-mediated formation of hemin3+ in turn increases the 
cathodic current as more hemin3+ is available for electrochemical reduction. The overall increase 
in current is dependent upon the concentration of superoxide as dictated by the reaction with rate 
kB. Similarily, if we examine the scenario when scanning positively, the opposite is true. 
Superoxide artificially increases the concentration of hemin2+ by reducing hemin3+. 
 
 
Figure 3-7 Superoxide Detection form GCE Electrode 
The CV scan range used to detect superoxide shows no increase in the presence of superoxide for glassy carbon 
electrodes with or without hemin adsorption (scan rate = 100 mV/s). 
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Catalase was added to the system to remove any interfering hydrogen peroxide that 
would be produced by the spontaneous dismutation of superoxide. Reagents for the xanthine 
oxidase system were added in a step-wise fashion to determine the specificity of the detection 
setup. The current at the oxidation peak at ~ - 400 mV was evaluated for superoxide detection. 
Without a PEDOT/GO film, little hemin is adsorbed to the surface of pristine glassy carbon 
electrodes as indicated by the lack of any true peak in the base CV (Figure 3-7). Furthermore, 
little to no increase in current is observed following addition of the superoxide generating 
system. 
As demonstrated earlier, hemin is effectively adsorbed to the surface of PEDOT/GO 
mainly due to the strong π-π interactions between the porphyrin and the graphene oxide. After 
addition of xanthine oxidase and catalase to the system we see no response in the oxidation peak 
at – 400 mV. However, effective superoxide detection is observed following addition of the 
substrate pterine. Once pterine is added to the reaction, a consistent increase in peak current is 




Figure 3-8 AdHemin-GO/PEDOT Sensing Peak 
In the presence of superoxide (generated by 30 mU/mL xanthine oxidase with 100 µM pterin) the oxidation peak of 
hemin adsorbed on the GO/PEDOT electrode increases in detectable current.  
 
Finally, by ranging the concentration of xanthine oxidase and measuring the peak current 
response, a calibration curve was constructed for the hemin sensor (Figure 3-9). The hemin-
GO/PEDOT sensor showed linear sensing capabilities at low concentrations of xanthine oxidase, 




Figure 3-9 Calibration Curve for Hemin-GO/PEDOT Sensor. 
The peak current increase measured by the Hemin-GO/PEDOT sensor was plotted vs concentration of xanthine 











3.3.3 Use of Hemin Electrode for Mechanistic Superoxide Study 
To evaluate the performance of the hemin-PEDOT/GO electrode, we completed a 
mechanistic study of the xanthine oxidase-pterin superoxide generating system. As mentioned 
previously, the xanthine oxidase system is a widely accepted method for producing biologically 
relevant sources of superoxide.25, 30 When the enzyme substrate is kept high in excess, the rate of 
superoxide production is maintained at a consistent rate (rate = k1) until the substrate 
concentration is diminished (Figure 3-10). However, as the production of superoxide increases, 
the probability of spontaneous dismutation also increases (rate = k2) until the two reactions are in 
equilibrium. With the addition of catalase, the product of spontaneous dismutation, hydrogen 
peroxide, is immediately removed. At equilibrium, the concentration of superoxide is constant 
until the concentration of pterin is diminished. 
 
Figure 3-10 Superoxide Production and Dismutation Scheme 
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By measuring the electrochemical detection of superoxide using the hemin-PEDOT/GO 
electrode, we were able to map out the mechanism described above (Figure 3-11). To track the 
production of superoxide over time, the peak current (substracted from baseline) was plotted 
across time. After the addition of catalase and xanthine oxidase to the system, the peak current 
remained stable with a small electrochemical drift. Without pterine the rate of superoxide 
production is k1 ~ 0 and there is not production of superoxide. However, following injection of 
pterine into the system, there is a short-lived time period where k1 > k2. During this interval, 
superoxide concentrations are increasing through the xanthine oxidase-pterin reaction and we 
observe an increase in peak current detected by the sensor. As the concentration of superoxide 
increases, the rate of spontaneous dismutation rapidly increases until the point when k1 ~ k2. The 
reaction has reached equilibrium and the hemin-PEDOT/GO sensor maintains a constant current. 
Small impulses of xanthine oxidase are not great enough to break through the equilibrium 
conditions until a large enough bolus is added. Once the xanthine oxidase concentration is 
increased enough, the rate of the production of superoxide is greater than the maximum 
dismutation rate (k1 >> k2). At this point superoxide generation increases and we observe a 
dramatic upswing in the peak current measured by the hemin-PEDOT/GO sensor. The current 
increases until the pterin substrate is exhausted at which point superoxide generation ceases, 
dismutation dominates, and the peak current begins decreasing back to pre-superoxide levels. 
Not only is the sensor effective at predicting the well-understood xanthine oxidase mechanism, 




In a separate sample, cytochrome c is added to the xanthine oxidase-pterin reaction. As 
superoxide is generated, cytochrome c is oxidized and increases in absorbance. Once the pterin is 
























Figure 3-11 Superoxide Detection of Enzymatic Generating System 
The Hemin-GO/PEDOT electrode was used to detect superoxide in a mechanistic study. Following the addition of 
the superoxide reagents, CV (scan rate 100 mV/s) were recorded. The peak current at – 0.55 V was plotted over 
time. The rate constants, k, refer to the constants described in Figure 3-9. (Insert) The absorption of cytochrome C 
was used to measure superoxide generated by the xanthine oxidase system. In the presence of xanthine oxidase and 






The ability to detect superoxide with a new hemin-PEDOT/GO electrode was investigated in this 
work. Unlike in the case of pristine glassy carbon electrodes, the metalloporphryin complex, 
hemin, readily adsorbed to the surface of PEDOT/GO modified electrodes as evidenced by the 
oxidation and reduction peaks of the electrode. The hemin modified PEDOT/GO electrode was 
effective at detecting superoxide production using cyclic voltammetry measurements. By 
recording peak oxidation current across time we were able to effectively track superoxide 
production using a mechanistic study of the enzymatic production of superoxide using xanthine 
oxidase. The development of this superoxide sensor could provide a new tool for understanding 
the role that superoxide plays in neurodegeneration as well as a diagnostic tool for determining 
the oxidative environment near chronically implanted neural electrodes.  
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4.0  IMPROVED L1 COATING OF PAYRLENE NEURAL ELECTRODES FOR USE IN 
NON-HUMAN PRIMATES 
4.1 INTRODUCTION 
The improvement of the tissue-electrode interface is essential for the development of promising 
neuroscience-based technologies such as neural prosthetic devices. One method of improving the 
abiotic/biotic interface is to ‘mask’ the implanted device using biomimetic strategies. Developed 
in our laboratory, a protein coating based on the neural cell adhesion molecule L1 has 
demonstrated great potential for improving neural electrode devices.46, 47, 87, 88  
L1 is a glycoprotein and part of the immunoglobulin family. Important during the 
development and differentiation of new neurons, L1 functions as a homophilic binding site 
between neurons.48, 49, 89 Due to the ability to improve neurite attachment and outgrowth in vitro, 
L1 has previously been used to improve the interface between silicon-based neural probes and 
the CNS.46, 47  Furthermore, L1 coatings decrease microglia and astrocyte recruitment, thereby 
reducing the main sources of ROS/RNS found in the inflammatory response.46 However, while 
L1 coatings have effectively improved the implantation site of silicon-based probes, little work 
to this point has been done on other probe designs and materials more closely ready for clinical 
use.  
 71 
Poly(2-chlor-para-xylylene), or parylene C (PC), is a widely used material due to its 
unique combination of flexibility, electrical properties, as well as biocompatibility.90-96 For this 
reason, biomedical devices including pace makers and deep brain stimulating electrodes often 
use parylene C as the insulating material. However, in the field of neural prosthetics, the 
performance of PC-based chronically implanted neural electrodes remains too unreliable for 
clinical acceptance.  
Using the FDA-approved penetrating micro-electrode array, the BlackRock Utah Array, 
we applied our L1CAM biomimetic coating to a device of clinical relevance. By using the Utah 
Array, we have translated our technology from silicon-based applications to the unique 
chemistry and practical design of the PC-based array. We analyzed the performance of PC 
coated samples for chemical modification, in vitro bioactivity, and electrophysiological testing in 







4.2 MATERIALS AND METHODS 
4.2.1 Chemicals and Reagents 
For isolation of L1 via immunoaffinity chromatography, 3((3-chloamidopropyl)dimethyl-
ammonio)-propanesulfonic acid (CHAPS) was purchased from Anatrace, and all other reagents 
and solvents including diethylamine hydrochloride and (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) (HEPES) were purchased from Sigma Aldrich. The parylene 
dimer (dichloro-di-para-xylylene, SCS DPX-C) was purchased from Specialty Coating Systems 
(Indianapolis, Indiana). E18 Sprague-Dawley rat cortices were purchased from BrainBits, LLC 











4.2.2 Isolation and Characterization of L1 Neural Adhesion Molecule 
Isolation of the cell adhesion molecule L1 from both Sprague dawley and Rhesus macaque was 
achieved using the same method described previously.49 An affinity column containing the 5H7 
monoclonal antibody bound to Affi-Gel 10 (Bio-Rad) was supplied by Carl Lagenaur for 
purification of L1. Brain tissue was first homogenized and isolated using sucrose gradient 
differential centrifugation. Membrane tissue was then solubilized in 1% CHAPS and centrifuged 
at 40,000 g for 30 min to remove any contamination. The membrane solutions are run over the 
column at a rate of approximately 1 mL/min. For elution of the bound L1 from the column, 0.1 
M diethylamine at a pH of 11.5 was used. Neutralization of the eluted L1 soltuion was achieved 
using 1 M (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) in H2O. L1 samples 
were used as prepared and required no additional processing. Elution from the column was 
tracked using the Amdio Black method. L1 solutions were spotted directly onto nitrocellulose 
membrane and submerged in Amido Black (MeOH) to visualize protein spots.  
4.2.3 Parylene Coating 
Chemical vapor deposition of parylene onto glass substrates was completed using the Special 
Coating Systems Labcoter® 2 Parylene Deposition System. For the deposition of > 1µm thick 
parylene-C, 1 g of DPX-C dimer was loaded into the deposition system. Prior to coating, glass 
coverslips (Dia. 8 mm, #1.5 Thickness, Electron Microscopy Sciences, Hatfield PA) were 
ultrasonicated in acetone then MeOH/H2O. Samples were kept in a closed container prior to and 
after parylene C coating.  
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4.2.4 L1-Modification of Parylene Samples 
Parylene-C coated coverslips were coated with L1 protein via protein adsorption. Dry parylene-C 
coated coverslips were exposed to oxygen plasma (30 W) for 1 min (Harrick Plasma, PDC-001). 
Oxygen flow into the plasma chamber was maintained at 1 L/min and pre-flushing of the 
chamber occurred for 15 min prior to generating plasma. Successful oxygen plasma was 
indicated by the blue hue of the plasma (as opposed to the traditional purple hue from air 
plasma). Oxygen plasma treated samples were immediately used for protein adsorption. Isolated 
L1 samples were applied directly onto parylene-C samples and allowed to adsorb for 1 hr. 
Samples were washed repeatedly with 1 X PBS prior to being used for cell culture experiments. 
To determine the coating quality, some samples were washed with 0.5 % Tween in PBS.  
4.2.5 Primary Neuron Culture 
Primary neuron cultures were prepared as described above (2.2.7). L1 bioactivity after preparing 
parylene-C coated samples, was verified with primary neuron cultures. E18 Sprague-Dawley rat 
cortices were purchased from BrainBits, LLC. The rat cortices were triturated with a 1 mL 
pipette and removed from the Hibernate MediaTM via centrifugation at 800g for 1 minute. Cells 
were re-suspended in Neurobasal (Fisher)/B27 (Gibco)/0.5 mM glutamine/25 µM glutamate 
(Sigma-Aldrich) culture medium and plated directly onto either coated samples in 48-well cell 
culture plates (Corning Costar) at a density of 2.5 x 105 cells/cm2. Cells were grown in culture 
for 5 days at 37 °C in 5% CO2 and media was refreshed after day 3. Cells were fixed with 4% 
paraformaldehyde for 10 min. and stained with the monoclonal antibodies against neuronal class 
III β-tubulin (Covance). 
 75 
4.2.6 Preparation of Functional Probe Coating Chamber 
For coating of the BlackRock (Salt Lake City, Utah) Arrays, a special coating fluidics chamber 
was designed. The device for coating micro-electrodes (CoatME) was designed to support the 
array during ETO sterilization, storage, L1 coating, and transport. Using stereolithography (SLA) 
3D printing, the chamber was printed with the WaterShed XC 11122 material, which is classified 
as biocompatible and chemical resistant according to ISO 109993. For in vivo experiments, a 
Utah array was loaded into the CoatME and sterilized with ETO. On the day of surgery, the array 
was exposed to oxygen plasma for 1 min (30 W, Harrick Plasma, PDC-001). The prepared 
monkey L1 solution was injected into the chamber using sterile tools in a sterile culture hood, 
and first passing through a 0.2 µm sterile filter. After 1 hr, the chamber was flushed with sterile 
PBS and transported to the surgical room. 
4.2.7 Impedance Characterization of Utah Arrays 
Impedance spectroscopy was used to monitor the electrode interface quality over time. Using an 
Autolab potentiostat, complex impedance was measured on a monthly basis by applying a 25 
mV RMS sine wave with frequencies varied logarithmically from 10 Hz to 100 kHz. Impedance 
measurements were extracted at 1 kHz and plotted over time. The average 1 kHz impedance 
magnitude was averaged across all electrodes on an array and compared with using the Student’t 
t-test for unpaired data (p-value of < 0.05 is considered significant). 
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4.2.8 Non-Human Primate Implantation of Utah Arrays 
Utah arrays with or without the L1 coating were transported for non-human primate implantation 
in the laboratory of Dr. Andy Schwartz. The 10 x 10 Blackrock Arrays were implanted 
bilaterally into the M1 cortex of the rhesus macaque using a similar approach as described 
previously.97 All surgery was completed under gas isoflurane anesthesia. A craniotomy was 
created above the target location, in the M1 area. Both arrays were positioned near the implant 
location and fixed to the surface of the skull. In the case of the L1 array, it was kept moist by 
spraying sterile saline directly onto the probe. After the dura was opened, and the target area 
identified, the arrays were inserted using a pneumatic inserter. The original bone flap was 
replaced prior to closing of the craniotomy. All animal use and procedures were in accord with 
the Institutional Animal Care and Use Committees at the University of Pittsburgh. In addition to 
impedance measurements, electrophysiology recordings were measured using a Tucker-Davis 
Technologies (TDT) system.  
4.3 RESULTS AND DISCUSSION 
4.3.1 L1 Isolation and Bioactivity 
The isolation of the L1 cell adhesion molecule (L1CAM) and L1CAM homologues has been 
achieved in a wide variety of species including rodents, fish, and even the fruit fly.48, 49, 89 
However, to our knowledge the isolation and characterization of non-human primate L1CAM 
has yet to be described. While isolation of Sprague dawley L1CAM has been successfully 
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isolated and applied to neural electrodes in our laboratory46, 47, the isolation of Rhesus macaque 
L1CAM was essential to prevent unwanted immunogenic responses in non-human primate 
neural electrode studies. 
 L1CAM protein from Rhesus macaque was isolated from fresh brain tissue. Following 
membrane extraction, protein fractions were collected in 1 mL aliquots and tested for protein 
content, purity, and bioactivity. Fractions that indicated positive protein content using the Amido 
Schwartz protein detection assay were evaluated for protein purity using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Isolation of pure L1CAM samples were 
verified by SDS-PAGE bands at ~ 240 kDa and ~ 150 kDa (Figure 4-1). L1 is a ~ 200-250 kDa 
cell surface protein; however, the band at ~ 150 kDa is a cleavage product that becomes cleaved 





Figure 4-1 SDS-PAGE Gel of Isolated L1 Fractions 
Lane 1 is a protein standard and lanes 1 – 3 are isolated L1 fractions. Pure L1 fractions can be identified by clear 
bands at ~ 240 kDa and ~ 150 kDa.  
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Bioactivity of purified L1CAM fractions was verified using a simple neuron cell culture 
assay on nitrocellulose coated samples. Following preparation of nitrocellulose coated culture 
dishes, aliquots from each isolated L1CAM fraction were pipetted onto designated areas on the 
dish. Fractions that resulted in ‘spots’ with robust neuron coverage were deemed bio-active. In 
spots without L1CAM, no neurite growth is observed. In addition to neurite growth on bioactive 
L1CAM spots, neuron growth was characterized by un-fasiculated extension. Unlike other 
adhesion proteins like laminin, L1CAM results in individual axons readily growing across the 
coated surface (Figure 4-2). Whereas in the case of laminin, cell bodies often spread out onto the 




Figure 4-2 Nitrocellulose Bioactivity Assay for Isolated L1 Fractions 
Primary rat neurons were cultured on nitrocellulose samples with or without monkey L1 protein. Cells plated 
directly onto nitrocellulose show minimal neurite extension. Conversely, L1 coated nitrocellulose results in neurite 
extension of cells.  
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4.3.2 Preparation of L1-Modified Parylene C Substrates 
Parylene materials are frequently the coating of choice for implantable devices from 
peacemakers to neural electrodes such as the BlackRock Utah Array.92 Halogenated derivatives 
like parylene C (chlorinated along the –para position) are increasingly implemented for these 










Figure 4-3 Structure of Parylene C 
 
 Prior to modification of the parylene-C on the BlackRock Utah Arrays for in vivo studies, 
it was necessary to demonstrate effective modification of parylene substrates and subsequent 
bioactivity of coated samples. Plasma treatment of polymer surfaces has proved to be a vital tool 
for materials scientists. Plasma treatment can be used to alter several characteristics of a surface 
including biocompatibility, cell adhesion, and protein adsorption.91, 98 When the plasma is 
generated from O2 gas, the hydrophilicity of the treated surface is increased through the 
generation of C-O and O=C-O bonds onto the surface. While the oxidation reaction sites are 
generally nonspecific, following O2 plasma treatment of parylene-C samples we observe sharp 




Figure 4-4 XPS Analysis of Parylene C Oxygen Peaks.  
Following oxygen plasma treatment of unmodified parylene C substrates, incorporation of oxygen is indicated via 
the XPS peak at 532 eV.  
 
Chemical state information is an effective method for determining changes to surface 
chemistry. Following O2 plasma treatment we observe a shifting of traditional Carbon 1s peaks 
due to the increase in C-O and O=C-C bonds. Following oxygen plasma treatment XPS 
experiments demonstrate the formation of carboxylic acid groups on the parylene-C surface 




Figure 4-5 Depth of Parylene C Surface Modification. 









Typically an increase in the hydrophilicity of a surface via O2 plasma treatment decreases 
the level of protein adsorption onto the surface. However, this is not the case with glycoproteins 
such as L1CAM where the opposite trend is in fact observed.99, 100  To verify this trend, we 
adsorbed L1CAM on parylene-C samples with or without prior O2 plasma treatment (Figure 
4-6).  As is the case with L1-positive spots on nitrocellulose, neurons plated onto L1-coated 
parylene-C samples were characterized with long neurite projections. This L1-specific growth is 
not observed on pristine parylene C samples. Few neurites are ever observed on unmodified PC 
samples. The extensive neurite projection demonstrates effective preparation of a L1-PC coating 
with retained bioactivity.  
 
 
Figure 4-6 L1 Adsorption on Oxygen Plasma Treated Parylene C 
Primary rat neurons were cultured on parylene C substrates with or without L1 adsorption. Adsorption of L1 was 
achieved following 1 min exposure to oxygen plasma. Neurons plated onto L1 coated samples demonstrate 




Dissemination of novel coating strategies for neural implants requires adaptation of 
traditional coating procedures. To that end, we designed a fluidics-based coating chamber in 
order to effectively coat BlackRock Utah Arrays without the risk of damaging the delicate 
microelectrode tips. A biocompatible printing resin (WaterShed XC 11122) was used to 3D print 
a chamber that would satisfy clinical needs for handling, storage, and coating of neural implants 
(Figure 4-7).  
 
 
Figure 4-7 CoatME Device for Utah Array Coating Procedure 
 
Prior to in vivo studies, we first verified that the CoatME device could effectively coat a 
BlackRock Utah Array. A Utah Array was loaded into the chamber and exposed to a similar 1 
min O2 plasma treatment as used for previous in vitro experiments. Following the plasma 
treatment, a solution of 100 µg/mL FITC-Albumin was injected into the chamber. Using 
fluorescence microcopy we demonstrated that fluorescently labeled protein effectively adsorbed 




Figure 4-8 FITC-Albumin Adsorption on Surface Treated Utah Array 
Following oxygen plasma treatment, FITC-albumin was adsorbed onto Utah Arrays using the CoatMe device. 
Following adsorption, the green fluorescent FITC-albumin protein is observed using fluorescent microscopy. (Left) 
Before FITC-albumin adsorption (Right) After FITC-albumin adsorption.  
4.3.3 Functional Study of L1-Coated Utah Arrays in Non-Human Primates 
To determine the effect of the L1 coating on the recording quality of neural implants, BlackRock 
Utah Arrays were implanted into the M1 cortical region of the Rhesus macaque. To reduce 
animal variance, control and L1-coated arrays were implanted into the same animal. Utah Arrays 
were coated using the CoatME device and transported to the lab of Dr. Andy Schwartz where all 
further surgical procedures and recording sessions were completed. After allowing the animal to 
recover, recording sessions were completed and neuron units were analyzed using custom 










Figure 4-9 Representative Neuron Spike Data 
Neural data collected from implanted Utah Arrays was thresholded into spike activity and sorted into isolatable 
units. 
 
Two non-human primate experiments have been started at this point (a third experiment resulted 
in early animal termination). The first animal has shown a remarkable improvement in isolatable 
neuron signals for multiple years following the implant (Figure 4-10). This is in stark contrast to 
the control array in the same animal which resulted in no recordable data after the first two 




Figure 4-10 Neural Recording of L1 Modified Utah Array 
The total number of units recorded form the implanted Utah Array coated with the L1 coating. The 
uncoated array stopped producing recordable units after 4 months. Units were grouped as the basis of total number 
of units per electrode from electrodes with only 1 recordable unit (Blue) to electrodes with 4 or more (Red).  
 
 
Current neuron quality data for the second implanted monkey is not significant; however, the 
time-point is still early. A noticeable trend is already apparent in the measured 1 kHz impedance 
data. As early as the first month after the implant procedure, the impedance on the array 
modified with the L1 coating is significantly higher. While impedance increases can be observed 
from a result of cellular interactions, without histological data the true mechanism behind this 
increase is currently unknown.12 Further recording sessions should elucidate the source of 
impedance difference between the arrays, and additional monkey implants will help to 





Figure 4-11 Impedance of L1 Coated Array Over Time. 
Magnitude impedance (Z), measured at kHz for 4 months following the implantation of L1 coated Utah Arrays. 
After the first month, the average 1 kHz impedance was significantly higher for the L1 modified probe compared to 
an unmodified array (± SEM; n = 96; * p < 0.05). 
 
4.4 CONCLUSIONS 
In this study we described the analysis and optimization of a biomimetic coating for parylene C 
based neural electrodes. Using XPS we demonstrated effective surface activation following 
oxygen plasma treatment. For the first time we have isolated the L1CAM protein in the non-
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human primate, Rhesus macaque. Using R. macaque L1CAM we effectively coated and 
demonstrated the bioactivity of coated PC samples in vitro using a primary neuron culture. In 
addition to improve the translational potential of the technology, we developed a new coating 
device, the CoatME, for handling, storage, and coating of FDA-approved neural electrode arrays. 
We demonstrated the effectiveness of this device and the benefits of the L1CAM coating by 
implanting coated Utah Arrays into the R. macaque and found a dramatic increase in neural 
recording quality for several years. By continuing to develop the L1CAM coating, this 
technology may improve the performance and thus clinical acceptance of neural electrode-based 
technology in the near future. 
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5.0  MESOPOROUS SILICA MAGNETIC NANOPARTICLES FOR NON-INVASIVE 
CONTROLLED DRUG DELIVERY 
5.1 INTRODUCTION 
Improvement of the interface between chronically implanted neural electrodes and central 
nervous system tissue (CNS) is believed to be a result of a combination of new coating 
strategies, electrode design, and treatment of nearby inflammation.1, 2 Regarding the latter 
methodology, treatment to the central nervous system is often made difficult by the limitations 
imposed by the blood-brain barrier (BBB).101 In order to supply the region near an implant with 
anti-inflammatory agents, cell survival factors, etc., new drug delivery systems are being actively 
researched. 
One of the most promising methods for drug-delivery into the CNS is through synthetic 
drug-carriers. Nanoparticles based on mesoporous silica are of great interest considering the 
biocompatible nature of silica nanomaterials.57, 102 Furthermore silica nanoparticles can be loaded 
with a wide variety of drugs, biomolecules, and other compounds of interest for the purposes of 
drug delivery. However, the inadequate control over drug-release from silica nanocarriers in 
combination with the lack of targeting specificity limits the potential of these materials. 
In order to improve the targeted drug release of silica nanoparticles, magnetic 
nanoparticles (MNP) are currently being researched.38, 43, 102 Magnetic nanoparticles have been 
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successfully incorporated into silica nanoparticles in order to increase the functionality of these 
nanomaterials. Silica magnetic nanoparticles (sMNP), like silica nanoparticles, can be loaded 
with a wide variety of molecules and have demonstrated the ability to cross the blood-brain 
barrier. These properties alone make sMNP a potential vessel for drug-delivery directly into the 
CNS.37, 38 Due to the magnetic nature of sMNP, these nanoparticles can be manipulated with 
magnetic fields to improve the targeting capabilities of the technology. By using static magnetic 
fields, sMNP have been previously targeted to CNS accumulation.37 In addition to tissue 
targeting, drug-release from sMNP can be controlled via application of a high-frequency 
magnetic fields.43  
In this work we describe the preparation of drug-loaded nanoparticles for the purpose of 
drug-delivery into the CNS. We have expanded upon earlier research by optimizing drug-release 
performance using high-frequency magnetic field. In order to translate the technology for clinical 






5.2 MATERIALS AND METHODS 
5.2.1 Chemicals and Reagents 
Reagents for magnetic silica nanoparticles were purchased from Sigma Aldrich including 
Fe(NO3)3·9H2O, silicon tetraethoxide (TEOS), HCl, and NaOH. For drug-loading experiments, 
ropivacaine was graciously supplied by Venkat Mantha MD (University of Pittsburgh Medical 
Center). Filtration devices (Amicon Ultra-0.5 NMWL 3,000) for nanoparticle separation were 
purchased from EMD Millipore. Dialysis tubing (3.5 MWCO) was purchased from Fisher 
Scientific. A modulated power supply was purchased from Accel Instruments for the 
construction of an alternating magnetic field coil.  
5.2.2 Synthesis of Mesoporous Silica Magnetic Nanoparticles 
Preparation of mesoporous silica magnetic nanoparticles (sMNP) was carried out using the sol-
gel process as described previously.43 Briefly, a silica sol was prepared with silicon tetraethoxide 
(TEOS), 2 N HCl, and absolute ethanol in the ratio of 41.6 g/10 mL/12 mL at room temperature. 
The sol was stirred at r.t. for 2 hr open to the atmosphere in a round bottom flask equipped with a 
magnetic stirrer. Following the 2 hr aging process, Fe(NO3)3·9H2O was dissolved in ethanol and 
added to the reaction in a ratio of Si/Fe = 1/1. To effectively load the model drug into the 
nanoparticles, the molecule of choice (ropivacaine/fluorescein) was added directly to the 
solution. To simultaneously hydrolyze the iron and deposit the silica, the pH of the solution was 
brought to pH ~ 2.7 with 1 N NaOH. However, care was taken to raise the pH slowly by adding 
in 100 µL NaOH every 2 min. to create uniform and reproducible sMNP. After the pH reached 
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2.7, the sol-gel was stirred for 24 hr. Experience demonstrated that repeated centrifugation and 
sonication resulted in aggregation, destruction, and pre-mature release of loaded drug from 
sMNP. To prevent these results, separation of sMNP from the reaction solution was achieved via 
dialysis. The acidic sol-gel suspension was transferred to SnakeSkin dialysis tubing (3.5 
MWCO) and dialyzed in Millipore water. The water was changed repeatedly over the course of 
24 – 48 hr until the pH of the water remained at pH ~ 7. The resulting sMNP water suspension 
was used as is for release experiments.  
5.2.3 Characterization of Magnetic Nanoparticles 
Morphology and uniformity of prepared sMNP were examined. The morphologies of the sMNP 
were examined under scanning electron microscopy (JEOL JSM-6510LV/LGS, SEM). 
Preparation of sMNP without aggregation was achieved by diluting nanoparticle suspensions 
1:100 in water and dropping 10 – 20 µL droplets onto gold coated silicon wafers that were being 
heated on a hot plate. Size and uniformity of sMNP were measured using a dynamic light 
scattering spectrometer (Brookhaven 90+ quasi-elastic light scattering spectrometer).  
5.2.4 Magnetic Coil Design and Stimulation 
Drug-loaded magnetic nanoparticles were exposed to high-frequency magnetic field 
(HFMF) to examine the release properties following external magnetic stimulation. For 
construction of a custom coil, litz wire was wound around a dielectric permeability core to 
produce a coil with inductance ~ 1 mH and DC resistance equal to 0.5 Ω. Current signals were 
driven by a bench top frequency generator and amplified using a modulated power supply from 
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Accel Instruments (TS200-0A, -5 A to + 5A). To achieve high field strengths at the examined 
frequency range (50 kHz – 100 kHz), the resonant technique was used to create RLC circuits 
where the coil and a given capacitor were in resonance. Samples of sMNP in PBS were loaded 
into glass tubes and were exposed at a variety of field strengths, frequencies, and durations. 
Following stimulation, samples were removed and filtered using Amicon Ultra-0.5 filtration 
devices. The filtrate was examined for drug release by collecting the absorbance spectrum and 
identifying the respective peak for the model drug. 
 
5.2.5 MRI Stimulation 
A 7 tesla human MRI scanner was used to generate gradient fields used for MRI-triggered 
release from sMNP. Prior to in vivo experiments, MRI-triggered release was demonstrated by 
measuring release from sMNP inside custom constructed dialysis sample tubes. Using the 
constructed dialysis sample tubes, sMNP suspensions were exposed to gradient field stimulation. 
The field was realized by applying a designed Echo Planar Imaging sequence (EPI). The applied 
gradient fields were about 1.7 kHz and the field intensity is 16 mT/m. The samples were placed 
at a location 80 cm away from the imaging iso-center in order to generate a 12 mT gradient field.  
For in vivo MRI-triggered, magnetic nanoparticles loaded with fluorescein (10 µL, 20 
mg/mL) were injected 2 mm into the rat brain. The rat skull was placed 80 cm away from the 
imaging iso-center and were exposed to 10 min gradient field stimulation (EPI, 1.7 kHz, 12 mT). 
Following the MRI gradient field, a contralateral sMNP injection was used as a control for 
sMNP release. The animal was immediately sacrificed, the brain removed, and flash frozen (-80 
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°C). Tissue was prepared by cutting 30 µm thick sections and slices were imaged using bright 
field microcopy to observe sMNP and fluorescence microcopy to observe fluorescein release.  
5.2.6 Preparation of Silica Magnetic Nanoparticle Coating 
Magnetic nanoparticles for use in coating experiments where prepared as described above; 
however, with the exception that no drug was loaded into the particles. Surface treatment of 
silica magnetic nanoparticles was carried out as follows. Silica magnetic nanoparticles (20 
mg/mL) in H2O were diluted into 150 mL methanol. The solution was mixed with equal amounts 
of glycerol and sonicated for 30 min. After sonication, the nanoparticles were transferred to a 
round bottom flask and 10 mL of APTES was added to the reaction. The reaction flask was 
heated to 85 °C in an oil bath and a hot plate equipped with a temperature probe. After 3 hr, the 
functionalized nanoparticles were transferred to a dialysis tube and dialyzed for 3 days. The final 
nanoparticle suspension in H2O was re-concentrated to 20 mg/mL via evaporation.  
Meanwhile, silanized glass coverslips were prepared as described above (2.2.4). 
Following attachment of the heterobifunctional cross-linker, the functionalized glass samples 
were submerged in the suspension of surface treated sMNP (20 mg/mL). After, 1 hr the samples 
were rinsed with water and used for primary neuron culture experiments.  
5.2.7 Primary Neuron Culture 
The effect on neuron growth and proliferation from a sMNP coated surface was determined by 
plating primary neurons directly onto sMNP-coated glass samples. E18 Sprague-Dawley rat 
cortices were purchased from BrainBits, LLC. The rat cortices were triturated with a 1 mL 
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pipette and removed from the Hibernate MediaTM via centrifugation at 800g for 1 minute. Cells 
were re-suspended in Neurobasal (Fisher)/B27 (Gibco)/0.5 mM glutamine/25 µM glutamate 
(Sigma-Aldrich) culture medium and plated directly onto either glass or sMNP coated glass 
coverslips in 24-well cell culture plates (Corning Costar) at a density of 2.5 x 105 cells/cm2. 
Cells were grown in culture for 5 days at 37 °C in 5% CO2 and media was refreshed after day 3. 
Cells were fixed with 4% paraformaldehyde for 10 min. and were imaged under bright field 
microscopy to determine cell growth. 
5.2.8 Release Measurements 
Release of ropivacaine and fluorescein were quantified using a Spectromax M5 
spectrophotometer. Following release, concentration of ropivacaine and fluorescein were 
determined by measuring the absorance (λ ~ 230 nm) or fluorescence (λex/em ~ 490/520 nm), 
respectively. Concentrations were determined by creating a calibration curve from a dilution 
series. Averages of release solutions were compared using the Student’s t-test (p-value > 0.05). 
5.3 RESULTS AND DISCUSSION 
5.3.1 Characterization of Synthesized Magnetic Nanoparticles 
Mesoporous silica materials have grown in importance for new biomaterials given the 
combination of biocompatibility in addition to the capacity for drug loading and delivery.57 By 
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combining the properties of silica nanomaterials with the capabilities of magnetic materials, we 
have engineered a system for controlled drug release (Figure 5-1). 
Using the sol-gel process we were able to create silica magnetic nanoparticles 
encapsulating a drug of interest. To model drug-release we loaded the nanoparticles with two 
different molecules. Firstly, we loaded the nanoparticles with ropivacaine, a common anesthetic. 
While ropivacaine is an effective anesthetic, low concentrations enter the blood stream could be 
fatal. Therefore, controlled and targeted drug release are essential for proper administration. For 
MRI experiments we used the model drug fluorescein for in vivo visualization purposes. 
By combining the base catalyzed hydrolysis of magnetic nanoparticles with the 
hydrolysis of tetraethyl orthosilicate, mesoporous silica magnetic nanoparticles could effectively 
be prepared in a single step.  
 
 
Figure 5-1 Design of Silica Magnetic Nanoparticle Drug Release Paradigm 
Silica magnetic nanoparticles were prepared and loaded with model drug using the sol-gel process. Release of drug 
from the nanoparticles was monitored following exposure to high-frequency magnetic field stimulation.  
 
 Following preparation of sMNP, the nanoparticles retained the magnetic properties of 
typical iron oxide nanoparticles, demonstrating the capacity for magnetic separation (Figure 5-2). 
However, characterization of silica based nanomaterials can prove to be difficult. Without care, 
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sol-gel networks can easily form resulting in polymerized ‘islands’.58 In order to properly image 
nanoparticles under scanning electron microscopy, a combination of alcohol dehydration as well 
as fast-drying techniques were used. Nanoparticles imaged with these conditions demonstrated 
uniform spherical shape and ‘nano’ scale size (Figure 5-2). 
 
 
Figure 5-2 Scanning Electron Microscopy of Silica Magnetic Nanoparticles.  
SEM images of prepared silica magnetic nanoparticles were collected using dilute samples to prevent aggregation. 
The observed nanoparticles were uniform in size and spherical in shape. 
 
 While SEM techniques allowed for a general observation of the size and morphology of 
the prepared nanoparticles, we relied upon the more quantitative nature of dynamic light 
scattering (DLS) particle size analysis for accurate representation of the uniformity of the 
nanoparticles.  DLS results verify that prepared sMNP were of the ‘nano’ size roughly ~ 150 nm 





Figure 5-3 Size and Distribution of Drug Loaded Magnetic Nanoparticles.  
Dynamic light scattering correlation spectroscopy using a NanoBrook 90Plus particle analyzer was used to 
determine the size and distribution of fluorescein loaded magnetic nanoparticles. The effective diameter of the 
synthesized nanoparticles was 154.5 nm with a polydisperisity index of 0.166. 
 
5.3.2 Drug-Release Performance via Magnetic Stimulation 
Loading drugs into silica magnetic nanoparticles creates a valuable technology for drug delivery 
that can be stimulated with a noninvasive magnetic stimulation paradigm. Prior to demonstrating 
the release of drugs from sMNP, the stability of the nanoparticles was evaluated. Nanoparticle 
suspensions were incubated at room temperature and physiological temperature for 24 hr. 
Following 24 hr, there was not a significant difference in the amount of passive ropivacaine 
released between samples at room temperature and samples incubated at physiological 
temperatures (Figure 5-4). Further experiments demonstrated that significant release could be 
stimulated by placing nanoparticle suspensions in 80 °C (data not shown).  
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Figure 5-4 Temperature Stability of Ropivacaine Loaded Silica Magnetic Nanoparticles.  
Passive ropivacaine release following synthesis was measured at both room and physiological temperature (λ ~ 230 
nm; ± SEM; n = 3; * p < 0.05). 
 
 Once we had verified the stability of the nanoparticles, we tested the effect of high-
frequency magnetic stimulation on the release properties of the sMNP. Using a 4G magnetic 
field created by a home-built coil driven by an amplified frequency generator, we observed 
significant increase in ropivacaine release almost instantaneously (Figure 5-5). The magnetic 
triggered drug release resulted in over a 100% increase in ropivacine when compared to the 24 hr 
passive release (room temperature). The increase between prolonged exposure to the high-
frequency magnetic field (60 min) and shorter durations was not significant, suggesting that the 
majority of the contents of the nanoparticles were released from a short impulse.  
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Figure 5-5 Time-Dependence of HFMF Triggered Drug Release. 
MNP-Ropivacine complexes (0.03 % w/v) were exposed to RF magnetic fields (4G, 50 kHz) for varying durations 
(± SEM; n = 3). Release following 60 min, and 10 min, exposures is statistically significant from passive release (24 
hr) (p < 0.05). Differences between exposure times are not statistically significant (p > 0.05) indicating only short-
term exposure time necessary for ropivacaine release. Ropivacaine release was determined by measuring the peak 
absorbance of the released solution after filtering the nanoparticles through 100K MWCO filters (λ = 230 nm). 
 
We also examined the importance of field strength on the release profile of magnetically 
triggered release from silica magnetic nanoparticles. At a field strength of 0.4 G, we observed no 
significant increase in drug release when compared to room temperature passive release (Figure 
5-6). However, intermediate drug release was observed following stimulation with a 2G 50 kHz 
field suggesting a close to linear response at the field strengths tested. Further testing is 
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necessary to determine the full extent of the field strength vs. drug release profile. However, due 
to the constraints of our circuit setup, power supply, and coil, a field strength of 4 G was the 
highest we could test.  
 
Figure 5-6 Field Intensity Dependence on HFMF Triggered Drug Release 
MNP-Ropivacine complexes (0.03 % w/v) were exposed to RF magnetic fields for 10 min. (50 kHz) at varying 
magnetic field strengths (± SEM; n = 3). Only release following exposure to 4G field strength is statistically 
significant from passive release (24 hr) (p < 0.05). 4G triggered release is also statistically different than release 
triggered with 2G and 0.4 G field strengths (p < 0.05). Ropivacaine release was determined by measuring the peak 




To examine the effects of frequency, we observed drug release under both high and low 
frequencies conditions. When looking at low frequencies, we compared a 1 kHz magnetic field 
to the standard 50 kHz field at 4 G. We found that low frequency stimulation was not capable of 
driving drug release from nanoparticles when the field strength was 4 G (Figure 5-7). Magnetic-
triggered drug release is thought to be a result of local hyperthermia caused by the motion of the 
iron oxide cores inside the mesoporous silica matrix.43 If the frequency of the magnetic 
stimulation is too low, then the required ‘motion’ of the iron oxide particles may not be great 










Figure 5-7 Low Frequency Dependence on HFMF Triggered Drug Release.  
MNP-Ropivacine complexes (0.03 % w/v) were exposed to RF magnetic fields (10 min, 4G) at varying RF 
frequencies (± SEM; n = 3). Only release following exposure to 4G field strength is statistically significant from 
passive release (24 hr) (p < 0.05). Ropivacaine release was determined by measuring the peak absorbance of the 
released solution after filtering the nanoparticles through 100K MWCO filters (λ = 230 nm). 
 
Likewise, we evaluated the impact that frequencies higher than 50 kHz had on the drug 
release from silica magnetic nanoparticles. However, due to the difficulties with driving high 
currents through inductors at high frequencies, we were unable to test 100 kHz at 4 G. Therefore, 
for the purposes of testing the 100 kHz frequency, we examined nanoparticle release at 50 kHz 
vs. 100 kHz at a field strength of 2 G (Figure 5-8). Unlike the trend we observed with low 
frequencies, there was no significant difference between higher frequencies. A possible source 
for this is most likely related to the relaxation time for the magnetic nanoparticles. The 
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commonly accepted hyperthermia mechanism requires agitation of the nanoparticles, increasing 
the local temperature, and resulting in drug release from the swelled nanoparticles.  As the 
frequencies increase, at a certain point the nanoparticles can no longer ‘move’ in phase with the 
stimulation.103 However, as we observed with the effect of field strength, the drug release 




Figure 5-8 High Frequency Dependence on HFMF Triggered Drug Release 
MNP-Ropivacine complexes (0.03 % w/v) were exposed to RF magnetic fields (10 min, 2G) at varying RF 
frequencies (± SEM; n = 3). Magnetic field-triggered release is statistically insignificant between 50 kHz and 100 
kHz stimulation. Ropivacaine release was determined by measuring the peak absorbance of the released solution 
after filtering the nanoparticles through 100K MWCO filters (λ = 230 nm). 
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5.3.3 Drug Release following MRI stimulation In Vivo 
A 7-Tesla human MRI scanner was used to test the ability of a clinical grade MRI to 
cause drug release of loaded nanoparticles in vivo. For the applied field, a gradient field was 
created using the designed Echo Planar Imaging sequence (Figure 5-9). Using the designed EPI, 
the maximum stimulation frequency that could be applied was 1.7 kHz. However, the gradient 




Figure 5-9 MRI Gradient Field Stimulation Paradigm 
(A) Gradient field generated by MRI gradient coil when applying designed EPI sequence. (B) Fourier transform of 
the applied fields. The major frequency component is ~ 1.7 kHz and intensity is about 16 mT/m.  
 
Given the high strength of the static field, 7T, a series of tests were conducted to verify 
that high field strengths alone would not cause drug release from nanoparticles. Nanoparticle 
(fluorescein loaded) suspensions were stored in various positions in the MRI scanner, and nearby 
rooms for 3 hr to determine the release properties. Static field (even at 7T) was not sufficient to 




Figure 5-10 Static Field Effects on Silica Magnetic Nanoparticle Drug Release 
MNP-FITC complexes were exposed to several different conditions for 1 hr. Afterwards the release of fluorescein 
was measured by first separating the nanoparticles via centrifugal filtration and then measuring fluorescence (λex = 
485 nm λem = 535 nm).  MRI positions 1 and 2 were inside the MRI instrument at different positions (7T static 
field). Samples in the basement, console room, and magnet room were tested for the effect of remnant fringe fields. 
The heated sample (80 °C) was used as a positive control for FITC release. 
 
Detection of fluorescein release from nanoparticles requires separation of the 
nanoparticles from the ‘release solution’ because nanoparticles scatter the light in the 
spectrophotometer detection equipment. Fluorescein loaded nanoparticles were placed into 





Figure 5-11 MRI Triggered Release In situ Design 
MNP-FITC complexes were loaded into constructed dialysis sample tubes. (A) The dialysis tube allows for 
diffusion of released fluorescein following triggered release while preventing the light scattering nanoparticles from 
interfering in the fluorescence measurements. (B) Localizer images demonstrate the contrast agent properties of the 
Magnetic Nanoparticles as they appear black in the MRI scan. 
 
Fluorescein loaded nanoparticles were placed into the dialysis tubes and placed into the 
MRI scanner. Fluorescence measurements of the dialyzed solution were measured every 10 min. 
to determine fluorescein release. After passive release had plateaued, MRI gradient field 





Figure 5-12 MRI Gradient Field Triggered Drug Release 
Using the custom built dialysis sample tubes, fluorescein release was detected over time following MRI stimulation. 
Magnetic nanoparticles loaded with fluorescein were loaded into the samples tubes and passive release was allowed 
to occur until fluorescein diffusion plateaued (~ 80 min.). Afterwards we applied echo planar (EPI) sequence to 
apply a stimulation ~ 1.7 kHz, 8mT 
 
Following our demonstration of the ability to trigger drug release from silica magnetic 
nanoparticles using a human MRI scanner, we moved on to a proof-of-concept study in the 
rodent brain. Magnetic nanoparticles were injected directly into the cortex of a Sprague dawley. 
The cortical region was then imaged using the MRI scanner (Figure 5-13). Once the region of 
interest was determined, the rat was exposed to the same gradient field used for the dialysis tube 
experiments. As a control, fluorescein loaded nanoparticles were also injected into a bilateral 





Figure 5-13 MRI Scan of Rodent Brain Target Site 
Images of rat central nervous system before magnetic nanoparticle injection (A) axial, (B) sagital. 
 
By sacrificing the animal and visualizing cortical slices with fluorescence microscopy, 
we were able to identify the nanoparticle injection site. Nanoparticles were easily identified by 
dark regions within the slice under bright field microscopy (Figure 5-14). In both cases (with or 
without gradient field stimulation), the nanoparticles were localized at the injection site and did 
not diffuse in the short time following the injection. Using fluorescence microscopy we observed 
a sharp contrast between nanoparticle sites with or without gradient field stimulation. Almost no 
visible fluorescein staining was observed in regions that were not exposed to MRI gradient 
fields. However, the nanoparticle injection site that was exposed to the 1.7 kHz EPI gradient 
field resulted in dramatic staining of the nearby tissue. Accumulation of the released fluorescein 




Figure 5-14 In Vivo Release of Fluorescein from MRI Triggered Silica Magnetic Nanoparticles 
Magnetic nanoparticles (10 µL, 20 mg/mL) were injected ~ 2 mm into the rat brain and exposed to 10 min. gradient 
field stimulation (1.7 kHz, 8 mT) or injected directly afterwards to serve as a control (no stimulation).  Following 
stimulation, the animal was immediately sacrificed, the brain removed and flash frozen (-80 °C). Sections were cut 
at 30 µm thick and slices were imaged using brightfield and fluorescence microscopy. Images depicted are at ~ 1300 
µm deep and using 10X magnification. Magnetic nanoparticles appear as a dark mass in the brightfield. Using 
fluorescence microscopy there is a clear increase in fluorescence in tissue surrounding magnetic nanoparticles 




5.3.4 Silica Magnetic Nanoparticle Coating 
Drug delivery to the central nervous system poses many problems, including the ability to cross 
the blood-brain barrier. We have effectively demonstrated that silica magnetic nanoparticles have 
great promise for noninvasive controlled drug release; however, delivery to the CNS still remains 
a major hurdle. However, by anchoring silica magnetic nanoparticles to the surface of neural 
probes we could create a drug release device on the surface of the probe that could be controlled 
via an externally delivered magnetic field. 
To create a silica magnetic nanoparticle coating, we first functionalized prepared 
nanoparticles with reactive functional groups. Silanol groups on the surface of magnetic 
nanoparticles can react in similar ways to an activated glass substrate.104, 105 Using the 




Figure 5-15 Silica Magnetic Nanoparticle Functionalization Scheme 
Functionalization of silica magnetic nanoparticles was completed using the organosilane linker, 3-




By functionalizing the nanoparticles with an amine group, we were able to use the 
coupling agent, GMBS, to couple the nanoparticles to a silanized surface. To that end we again 
used silane chemistry to functionalize the surface of glass. Once again the organosilane linker 
created a free amine group on the surface of our glass samples. The silane-functionalized glass 
samples were then reacted with the activated nanoparticles to couple the silica magnetic 
nanoparticles onto the surface of the glass (Figure 5-16). 
 
 
Figure 5-16 Silanization Scheme for Functionalized Silica Magnetic Nanoparticles. 
Preparation of silica magnetic nanoparticle coating was achieved via a dual-silane strategy. Silicon surfaces were 
treated with a thiol-containing organosilane and coupled to silanized nanoparticles using N-ɣ-maleimidobutyryloxy 
succinimide ester (GMBS).  
 
To determine the uniformity of the coating we examined the samples under scanning 
electron microscopy. Under SEM we observed that the nanoparticles were in fact coupled to the 
surface. The nanoparticles were also less prone to typical ‘island’ formations as seen when 
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drying free silica nanoparticles. However, uniform coverage of the nanoparticles were only 
observed at regions near the edge of the sample, suggesting elevated concentrations would be 
necessary for fully uniform samples (Figure 5-17). Interestingly, ‘cross’ shaped aggregations of 
the nanoparticles were observed that are not seen when drying nanoparticles directly onto glass 
samples. It is likely that these substrates may in fact be cross-linked nanoparticles when you 
consider the cross-reactivity for activated silica nanoparticles with amine-functionalized 
nanoparticles. The unique ‘cross’ shape could be a result of the magnetic moment of the 









Figure 5-17 Scanning Electron Microscopy of Silica Magnetic Nanoparticle Self-Assembled 
Monolayer.  
SEM Images of the silica magnetic nanoparticle surface show sub-micron nanoparticles coated onto the 
surface of the glass samples. A region of uniform coverage is observed at edges of the sample. Macro-structures are 










To determine the biocompatibility of the silica magnetic nanoparticle coating, we plated 
primary neuron cultures directly onto samples coated with the nanoparticles. Not only did 
neurons readily grow onto surfaces coated with the sMNP, but neurite extension rivaled what we 
observe with L1CAM coatings (Figure 5-18). The magnetic field of a neuron is a well-known 
phenomenon and the basis for such technologies as trans-cranial magnetic stimulation. In 
addition the relationship between magnetic fields of nearby neurons is thought to be important 
for development and is being manipulated for new nerve guide technologies. 52, 106 With this 
understanding, the magnetic nature of the coating may in fact be responsible for the neurite 
proliferation we observe in culture.  
 
 
Figure 5-18 Primary Neuron Proliferation on sMNP Coating. 
Primary neuron cultures were grown on the silica magnetic nanoparticle coating. Neurite growth and cell adhesion is 
observed in samples with the coating.  
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5.4 CONCLUSIONS 
To establish a new method for drug-delivery into the central nervous system, we have optimized 
the stimulation and release properties of silica magnetic nanoparticles. By combining the 
biocompatible properties of silica materials with the magnetic separation and controlled-release 
properties of magnetic nanoparticles, we have demonstrated a noninvasive method for controlled 
drug-release. In addition, we have adapted the technology for use with clinical grade MRI 
instrumentation and provided a ‘proof-of-concept’ for in vivo drug release into the CNS using a 
7-Tesla MRI scanner. Furthermore, for the purposes of improving the interface between neural 
tissue and implanted probes, we were able to anchor sMNP directly to the surface of silicon 
samples. Not only did our dual-silane method enable incorporation of sMNP into self-assembled 
monolayers, but we observed a remarkable improvement in neuron attachment and proliferation. 
Combined with the noninvasive drug-release techniques described, we have demonstrated the 
potential of sMNP for drug-delivery into the CNS in order to treat the inflammatory response 
nearby neural electrodes.  
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6.0  CONDUCTIVE POLYMER-MAGNETIC NANOPARTICLE NANOCOMPOSITE FOR 
IMPROVED ELECTROCHEMICAL DRUG-RELEASE 
6.1 INTRODUCTION 
New methods for controlled drug release are of great importance to the medical field, 
particularly for neural technologies considering the difficulty in targeted drug release into the 
central nervous system (CNS).107-110 Neural prosthetic technologies represent a unique 
circumstance where an electrically active device is implanted into the tissue. While the 
inflammatory response to such devices poses a problem to the development of a stable interface 
between host tissue and an inorganic material, the individual electrodes create potential sites for 
externally controlled drug release.61, 111 
Drug release from electrodes has increased in importance with the development of new 
conducting polymer nanomaterials. In addition to improved recording performance gained by 
deposition of conducting polymer films onto electrodes, these polymers enable drug-loading and 
subsequent drug-release into nearby tissue. Typically drugs loaded into the polymer, as dopants, 
are released by electrically stimulating the electrode and thereby ‘ejecting’ the drug into the 
surrounding area. However, the quantity of drug loaded is often restricted by the surface are of 
the material.  
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Recently materials combining both conducting and magnetic properties have gained the 
interest of scientists in fields ranging from electronics to optics.55 Nanomaterials with this dual-
functionality result in new methods of manipulation previously unexplored. However, combining 
the two materials for the purpose of drug-delivery has yet to be investigated. In this work we 
have prepared nanoparticles with both conductive and magnetic properties for the purpose of 
improving the drug-loading and release properties of electrodeposited nanofilms. 
6.2 MATERIALS AND METHODS 
6.2.1 Chemicals and Reagents 
For preparation of conductive-magnetic nanoparticles, ferrous sulfate, polyethylene glycol (PEG, 
Mn = 4000 g mol-1), FeCl3·6H2O, NaOH, H2SO4, HCl (37%), H2O2, polyviynyl alcohol (PVA), 
and pyrrole monomer were purchased from Sigma Aldrich. The pyrrole monomer was purified 
via vacuum distillation and stored frozen in a low-temperature desiccator.  
6.2.2 Synthesis of Conductive Magnetic Nanoparticles 
Fe3O4 magnetic nanoparticles were prepared using the following precipitation-oxidation method 
described previously.55 In a 3-neck round bottom flask, equipped with a condenser, magnetic stir 
bar, and nitrogen inlet, 70.0 g of PEG (Mw = 4000 g mol-1) was added to 3.0 g FeSO4·7H2O in 
140 mL H2O. The reaction was bubbled in N2 for 30 min and 0.6 mL of H2O2 (37%) was added. 
The temperature was increased to 50 °C and the PH increased to ~ pH 13 using 3M NaOH. After 
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24 hr, the magnetic fluid was dialyzed with SnakeSkin dialysis tubing (3.5 MWCO) in Millipore 
water for 48 hr. Afterwards, the magnetic nanoparticles were separated via magnetic field 
separation, repeatedly washed with Millipore water, and dried under vacuum.  
Incorporation of the Fe3O4 magnetic nanoparticles into Fe3O4-PPy nanoparticles was 
accomplished by chemical polymerization of polypyrrole around the previously synthesized 
magnetic nanoparticles. The in situ emulsion polymerization was carried out in a three-neck 
round bottom flask, equipped with a magnetic stir bar, nitrogen inlet, and condenser. Sodium p-
dodecylbenzenesulfnate (NaDS, 1.5 g) was dissolved in 90 mL H2O in the round bottom flask 
and stirred for 15 min followed by the addition of 500 mg Fe3O4 and 500 mg fluorescein. After 
an additional 15 min, 5 mL of pyrrole as added to the reaction and stirred for 1 hr. In a separate 
flask, FeCl3 was dissolved in water containing 12 mg/mL poly(vinyl) alcohol (PVA, Mw 13000-
23000) with an oxidant: monomer molar ratio of 0.5. The oxidant solution was then added 
dropwise to the reaction while on ice. The polymerization continued for 12 hr at 0-5 °C. The 
fluorescein loaded Fe3O4-PPy nanoparticles were dialyzed with Millipore water for 2 days and 
purified via magnetic separation. 
6.2.3 Preparation of Conductive Magnetic Nanoparticle Electrode 
The fluorescein loaded Fe3O4-PPy nanoparticles were electrochemically deposited onto gold 
coated silicon wafers with a chromium adhesion layer. The polymerization solution consisted of 
fluorescein loaded Fe3O4-PPy and an additional 0.5 M pyrrole monomer. For control samples, 
0.1 M fluorescein was added to the deposition solution. Polymerization occurred using a Gamry 
potentiostat, FAS3 femtostat (Gamry Instruments) using the traditional three-electrode system. 
The gold coated silicon wafer served as the working electrode in addition to a silver/silver 
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chloride reference electrode (CH instruments) and a platinum foil counter electrode. Prior to 
deposition, a static neodymium magnet was placed behind the electrochemical cell to locate the 
nanoparticles to the electrode surface. After approximately 2 min a visible change in the solution 
could be observed with the dark Fe3O4-PPy nanoparticles aggregated around the working 
electrode.  Polymerization was conducted at 0.8 V for 200s. Samples were soaked in PBS for 30 
min then rinsed in deionized water and allowed to air dry prior to release.  
6.2.4 Electrochemical Release 
Electrochemical release was conducted into fresh PBS. Fluorescein release from fluorescein 
loaded Fe3O4-PPy was stimulated by using a repeating negative potential. Each stimulation 
consisted of five repeats of a -1 V for 5 s interval followed by a 0 V for 5 s interval. Following 
release, samples were collected and fluorescence was immediately quantified on a Spectromax 
M5 spectrophotometer. Following release fluorescein in the solution was quantified by 
measuring the fluorescence (λex/em ~ 490/520 nm). Averages of release solutions were 
compared using the Student’s t-test (p-value > 0.05). 
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6.3 RESULTS AND DISCUSSION 
6.3.1 Preparation of Conductive Magnetic Nanoparticles 
Materials with both conductive and magnetic properties are extremely useful; however, little 
work has been done on the drug-release capabilities of such materials. We combined previously 
used methodology to create magnetic nanoparticles entrapped along with the model drug, 
fluorescein, in a larger polypyrrole conducting polymer nanoparticle (Figure 6-1).  
 
Figure 6-1 Synthesis Scheme for Magnetic-Conductive Nanoparticles 
 
Once we synthesized the particles, we verified size and morphology using scanning 
electron microscopy. The particles were roughly 200 nm in diameter and fairly uniform in size 
distribution (Figure 6-2). The nanoparticles demonstrated excellent magnetic separation 
properties while suspended in water. The incorporation of PVA was necessary for preparing 
suspendable nanoparticle preparations. Previous efforts to prepare conductive-magnetic 
nanoparticles without PVA resulted in insoluble particles that were unable to be dispersed in 




Figure 6-2 SEM of Prepared Magnetic-Conductive Nanoparticles.  
SEM images of the magnetic-conductive nanoparticles demonstrate spherical shape of prepared particles. 
 
6.3.2 Preparation and Release Performance for Conductive MNP Electrode Film 
Using the prepared conductive-magnetic nanoparticles we designed a release paradigm that is 
traditionally used to release drug from conducting polymer nanocomposites (Figure 6-3).61, 111 
However, because of the unique magnetic properties of the nanoparticles we were able to use 
magnetic separation techniques to increase the concentration of the nanoparticles at the surface 
of the electrode. By placing a neodymium magnet behind the working electrode during 
electrodeposition, a thick black coating was created. Additional pyrrole monomer was added to 




Figure 6-3 Electrodeposition of Magnetic-Conductive Nanoparticle.  
Electrodeposition was carried out using a two-step process. First nanoparticles were aggregated at the electrode 
surface using a neodymium magnet placed behind the electrode. Afterwards, electrodeposition was completed to 
polymerize polypyrrole. Electrical stimulation was used to trigger drug release from the prepared films. 
 
After deposition of the coating we examined both the PPy control and PPy/Fe3O4 films 
with scanning electron microscopy. As expected, the control film was smooth and evenly coated 
the morphology of the working electrode. The conductive-magnetic film was much different in 
morphology, characterized by rough, ‘birds-nest’ like structures covering the surface of the 








Figure 6-4 Scanning Electron Microscopy of Magnetic-Conductive Nanocomposite Film. 
SEM images illustrate the differences between nanocomposite films with or without magnetic-conductive 
nanoparticles. Polypyrrole films polymerized with fluorescein are smooth and coat the contours of the electrode 
surface (a). Polymerization in the presence of magnetic-conductive nanoparticles results in a rough, dense network 
(b). 
 
For electrochemically controlled drug release from the prepared films, electrodes were 
submerged into electrochemical cells containing fresh PBS. Electrodes were washed beforehand 
with copious amounts of PBS to wash away any loosely bound fluorescein/monomer. By 
exposing the cell to UV light we were able to visualize the release from the macro-electrodes 
(Figure 6-5). Release from the PPy/Fe3O4 film resulted in a bright green color change to the 
probe as well as the nearby solution (Figure 6-5). This change was not visible by eye in the 
control condition and demonstrated the dramatic increase in fluorescein release from the 




Figure 6-5 Electrochemical Release from Magnetic-Conductive Nanocomposite Film.  
Electrochemical release from magnetic-conductive nanocomposite results in immediate fluorescein release that can 
be visualized with a handheld UV lamp. 
 
We were able to quantify the fluorescein release to compare the control and PPy/Fe3O4 
films using fluorescence measurements of the release solution. Following electrochemical 
stimulation, we measured the fluorescein released and found that the PPy/Fe3O4 resulted in an 
increase of over 500% (Figure 6-6). This dramatic increase in fluorescein release is not 
surprising considering the extreme differences observed in the film morphologies of the two 




Figure 6-6 Quantitative Fluorescein Release from Magnetic-Conductive Nanocomposites 
Fluorescein concentration (λex/em ~ 490/520 nm) was measured following electrical stimulation of fluorescein-doped 
polypyrrole films (PPy/FITC) and the magnetic-conductive nanocomposite film (MNP/PPy/FITC). Release from the 









To improve the drug-loading and release of electroactive conducting polymer films we have 
developed a new conductive-magnetic nanocomposite.  By loading a conductive-magnetic 
nanoparticle with drug, we are able to create a densely loaded electroactive drug reservoir. Using 
the magnetic separation properties of the synthesized nanocarrriers, we were able to 
electrodeposit an extensive conducting polymer network on an electrode encapsulating the 
loaded nanoparticles. We have demonstrated that the prepared nanocomposite is capable of 
electroactive drug-release and outperforms the traditional doped-conducting polymer in storage 
by several folds.  
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7.0  CONCLUSION 
7.1 SUMMARY OF RESULTS 
This dissertation describes the development of new materials for the improvement of the neural 
electrode-tissue interface. Using fundamental theory and techniques from chemistry, molecular 
biology, and physics a wide variety of new platforms were developed. A new immobilizable 
SODm (iSODm) was prepared and demonstrated effective improvement of neuron survivability 
and reduction of oxidative environment. As a means for detecting oxidative stress in vivo, a new 
superoxide sensor was developed by combining a metalloporphyrin sensing element with the 
electrical properties of PEDOT/GO films. With the goal of translating the L1CAM biomimetic 
coating technology that has demonstrated the ability to promote neuron survival as well as 
prevent inflammation, efforts were placed on creating translatable technological improvements. 
Finally, using magnetic and conductive nanomaterials, new drug delivery systems were 
developed with clinical applications. 
The antioxidant SODm coating described in Chapter 2 was prepared with the hope of 
reducing oxidative stress around neural implants and therby improving neuron survivability. Not 
only was a new complex synthesized with high SODm activity, but it was combined with SAM 
technology to create an antioxidant surface coating. Using the iSODm coating, we demonstrated 
an elimination of superoxide produced by a stimulated microglia cell line. We also observed 
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evidence of a decreased inflammatory response as indicated by a decrease in ROS related 
enzyme activity. Initial acute (1 week) in vivo studies demonstrated the effectiveness of the 
coating to improve neuron density around implanted neural electrode probes.  
Whereas Chapter 2 focused on the creation of a new method for preventing oxidative 
damage, the focus of Chapter 3 was to produce a new diagnostic tool for in vivo oxidative stress. 
Building upon our laboratories previous success with PEDOT/GO based biosensors, we 
incorporated a superoxide sensing element into the film. With the prepared hemin-PEDOT/GO 
electrode we were able to effectively detect superoxide produced via the xanthine oxidase 
enzymatic system. In addition using this newly designed electrode, we were able to complete a 
mechanistic study of superoxide production.  
Chapter 4 expanded upon our previous work developing biomimetic coatings for neural 
implants. We were able to apply our knowledge of protein-based coatings to create a new coating 
strategy for parylene C based devices. In addition, for the first time we demonstrated isolation of 
non-human primate L1CAM for use in in vivo studies. Furthermore, we developed new practical 
coating strategies for applying the L1CAM technology to FDA-approved devices. Finally, using 
our translatable technology, we effectively demonstrated improvements in neural recording 
quality in non-human primate neural prosthetic experiments.  
To expand upon our ability for treatment of oxidative stress near neural implants Chapter 
5 details the development of new methods of non-invasively controlling drug release. Using a 
combination of silica and magnetic nanomaterials, we prepared nanoparticles that were 
responsive too externally applied magnetic fields. After demonstrating these materials could 
release loaded drug molecules following high-frequency magnetic field, we evaluated their 
performance in vivo. Using clinical grade instrumentation, we provided a ‘proof-of-concept’ 
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study indicating that these materials could be used to drive drug release in the brain tissue of 
living organisms. Finally to provide a platform for combining this technology with neural 
electrodes, we were able to prepare a magnetic nanocomposite coating on silicon based 
substrates. Surprisingly we demonstrated not only improved biocompatibility but a remarkable 
effect on improving neurite outgrowth.  
Finally, Chapter 6 describes an additional method for drug delivery into the central 
nervous system from implanted electrode technology. Combining our previous efforts of 
electrochemically controlled drug-release, with our emerging research in magnetic nanoparticles, 
we effectively created a new conductive-magnetic nanocomposite. Using magnetic separation 
and electrodeposition we prepared a new electrode film marked by a dramatic increase in surface 
area, roughness, and fibrous network. This coating demonstrated a remarkable improvement in 
terms of drug loading and release capabilities compared to traditional conducting polymer based 
designs.  
7.2 FUTURE DIRECTIONS AND PRELIMINARY DATA 
7.2.1 Functional Study of iSODm Electrode 
In this work we have described the beneficial effects of the iSODm coating resulted in 
antioxidant properties demonstrated in vitro as well an improved neuron density around neural 
electrodes implanted in vivo for 1 week. Due to these promising results, the technology is 
currently being tested with functional arrays. However, prior to use with functional neural probe 
packages, the practical design and chemical strategy had to be altered. For the purposes of 
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silanization of the neural probe in a moisture-free environment, a 3-neck flask was used that was 
equipped with a probe holder device (Figure 7-1). Furthermore, the traditional solvent used for 
organosilane chemistry, toluene, was incompatible with neural probe technology. We found that 
toluene vapors inevitably destroyed the epoxy coating covering the probe leads. We also 
evaluated a different method for the cleaning and activation of the silicon surface. For the safety 
of the probe, nitric acid cleaning was avoided. Instead, the probe was rinsed with acetone, 
followed by a 50% (v/v) MeOH/H2O solution. To remove organic debris, the probe was rinsed 
with chloroform. Finally, the array was exposed to O2 plasma for 1 min. To test the effectiveness 
of this coating strategy, we demonstrated that an L1CAM coating prepared in this manner 
effectively promoted neuron attachment (data not shown). 
 
 







To test the performance of chronically implanted neural probes, coated and unmodified 
probes were implanted into S. dawley rats for a functional recording study. Functional Michigan-
style Neuronexus probes (A1-LP style, 16 channels, 3 mm long, 100 µm site spacing, 703 µm2 
area) were implanted into the M1 of rat brain (1.5 mm anterior to Bregma, 2 mm lateral to the 
midline). Neural recording was completed using a TDT RX5 system. Recordings were done on 
awake, freely moving animals. Data was collected in 5 min blocks and spike data analyzed using 
the commercially available OpenSorter package (Figure 7-2).  
 
 
Figure 7-2 Representative In Vivo Neural Signal Quality 
 
Following 1 week we found a high percentage of channels in the layer 3-4 region of the 
cortex producing high signal-to-noise ratio (SNR) recordable units (Figure 7-2). At this time, 
multiple animals have been implanted and continue to provide excellent recording quality. Upon 
completion, data will be analyzed on the basis of SNR, recordordable unit yield, and impedance 




Figure 7-3 Electrode Array Recording Quality vs. Depth 
7.2.2 In Vivo Imaging of Oxidative Species 
Current analysis of oxidative stress and subsequent neurodegeneration around chronic 
neural electrodes is limited to histological end-point experiments. The short half-life and 
diffusion-limited reactions of reactive oxygen species make immunohistochemistry qualitative at 
best. With the use of dihydrorhodamine 123 (DHR 123), an indicator of ROS, the extent of 
oxidative stress in ex vivo human skin after exposure to UV light shows promise for directly 
visualizing ROS in tissue [23-24]. By combining in vivo imaging with the unique specificity of 
DHR 123 for peroxynitrite, it may be possible to visualize oxidative stress near a neural 
electrode in vivo and in real-time. 
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To test the ability to visualize an increase in oxidative species in vivo, we evaluated DHR 
fluorescence following stroke insult in the murine brain. In brief, following opening of a 
craniotomy location, the animal was injected with Rose Bengal (4,5,6,7-tetrachloro-2’,4’,5’,7’-
teatraiodofluorescein). Rose Bengal is used in animal models of ischemic stroke, through the 
creation of a thrombus in blood vessels following illumination by 561 nm light. Prior to 
excitation of the stroke-inducing rose bengal molecule, DHR was injected into the right 
hemisphere of the exposed brain tissue. As a control, rhodamine 123 (Rho123) was injected into 
the contralateral location. After the induction of stroke we observed an increase in the 
fluorescence of the tissue indicating oxidative production of Rho123 from the injected DHR 
(Figure 7-4).  This tool could be an effective method for understanding the role that oxidative 
species play around implanted neural electrodes.  
  
 
Figure 7-4 In Vivo Imaging of ROS Following Stroke 
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7.2.3 New Coating Strategy for Parylene C Materials 
Using adsorption of L1CAM directly onto parylene C surfaces, we demonstrated an 
improvement in the neural tissue-electrode interface. Building upon that technology we have 
continued ways to improve the coating. Chemical modification of parylene C substrates by 
covalently attaching proteins through EDC/NHS chemistry has previously been described.90 
However, the use of Friedel-Crafts reaction makes the chemistry less effective when working 
with delicate neural probes. To that end we adapted oxygen plasma treatment for direct 
modification of payrlene C substrates. By relying upon the formation of O = C – O bonds formed 
following O2 plasma treatment (described in Chapter 4), we directly modified surfaces with 
EDC/NHS linking chemistry. Following covalent attachment of L1CAM through the 
functionalized PC surface we demonstrated improved neuron attachment (Figure 7-5). Covalent 
strategies for L1CAM coatings will be effective at creating more long-term strategies for 
biomimetic coatings.  
 
 
Figure 7-5 Plasma Initiated Covalent Protein Immobilization on PC 
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7.2.4 Dual Coating Strategy L1 and iSODm 
The complex tissue response within the central nervous system (CNS) requires a 
multidisciplinary approach. Given our promising results with developing both a biomimetic 
coating as well as an antioxidant coating, we have combined the two technologies to improve the 
electrode interface. By adding the synthesized iSODm complex to the final step of silane-based 
coating technology (described in full detail in Chapter 2 and Chapter 4), we were able combine 
these two coating strategies. Neuron cultures with the dual L1/iSODm coating displayed 
properties found in both coatings. Like in L1 cultures, the neurites were extensive and 
unfasiculated (Figure 7-6). However, unlike L1 cultures and more resembling iSODm cultures, 
the cell bodies readily attached and proliferated on the surface of the coating. By combining 
these two techniques we may greatly improve the tissue-electrode interface through the 
synergistic action of a cell adhesion-antioxidant coating.  
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